<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Non‐corticosteroid adjuvant therapies for acute bacterial meningitis - Fisher, J - 2021 | Cochrane Library</title> <meta content="Non‐corticosteroid adjuvant therapies for acute bacterial meningitis - Fisher, J - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013437.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Non‐corticosteroid adjuvant therapies for acute bacterial meningitis - Fisher, J - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013437.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013437.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Non‐corticosteroid adjuvant therapies for acute bacterial meningitis" name="citation_title"/> <meta content="Jane Fisher" name="citation_author"/> <meta content="Lund University" name="citation_author_institution"/> <meta content="jane.fisher@med.lu.se" name="citation_author_email"/> <meta content="Adam Linder" name="citation_author"/> <meta content="Lund University" name="citation_author_institution"/> <meta content="Maria Grazia Calevo" name="citation_author"/> <meta content="Istituto Giannina Gaslini" name="citation_author_institution"/> <meta content="Peter Bentzer" name="citation_author"/> <meta content="Lund University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD013437.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/11/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013437.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013437.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013437.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acetaminophen; Adrenal Cortex Hormones [therapeutic use]; Anti-Bacterial Agents [therapeutic use]; *Hearing Loss; *Meningitis, Bacterial [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013437.pub2&amp;doi=10.1002/14651858.CD013437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="zCmos3jT";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013437\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013437\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013437\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013437\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ko","ms","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013437.pub2",title:"Non\\u2010corticosteroid adjuvant therapies for acute bacterial meningitis",firstPublishedDate:"Nov 23, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Acute Respiratory Infections Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=zCmos3jT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013437.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013437.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013437.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013437.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013437.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013437.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013437.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013437.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013437.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013437.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3544 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013437.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/full#CD013437-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/full#CD013437-sec-0116"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/full#CD013437-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/full#CD013437-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/full#CD013437-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/full#CD013437-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/full#CD013437-sec-0043"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/full#CD013437-sec-0110"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/appendices#CD013437-sec-0121"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/table_n/CD013437StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/table_n/CD013437StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Non‐corticosteroid adjuvant therapies for acute bacterial meningitis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/information#CD013437-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Jane Fisher</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/information#CD013437-cr-0005">Adam Linder</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/information#CD013437-cr-0006">Maria Grazia Calevo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013437.pub2/information#CD013437-cr-0007">Peter Bentzer</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/information/en#CD013437-sec-0138">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 November 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013437.pub2">https://doi.org/10.1002/14651858.CD013437.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013437-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013437-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013437-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013437-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013437-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013437-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013437-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013437-abs-0001" lang="en"> <section id="CD013437-sec-0001"> <h3 class="title" id="CD013437-sec-0001">Background</h3> <p>Acute bacterial meningitis is a bacterial infection of the membranes that surround and protect the brain, known as the meninges. The primary therapy for bacterial meningitis is antibiotics and corticosteroids. Although these therapies significantly improve outcomes, bacterial meningitis still has a high risk of death and a high risk of neurological sequelae in survivors. New adjuvant therapies are needed to further reduce the risk of death and neurological sequelae in bacterial meningitis. </p> </section> <section id="CD013437-sec-0002"> <h3 class="title" id="CD013437-sec-0002">Objectives</h3> <p>To assess the effects of non‐corticosteroid adjuvant pharmacological therapies for mortality, hearing loss, and other neurological sequelae in people with acute bacterial meningitis. </p> </section> <section id="CD013437-sec-0003"> <h3 class="title" id="CD013437-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, CINAHL, and LILACS databases and ClinicalTrials.gov and WHO ICTRP trials registers up to 30 September 2021, together with reference checking, citation searching, and contact with study authors to identify additional studies. </p> </section> <section id="CD013437-sec-0004"> <h3 class="title" id="CD013437-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) of any pharmacological adjuvant therapy for acute bacterial meningitis. </p> </section> <section id="CD013437-sec-0005"> <h3 class="title" id="CD013437-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed and extracted data on methods, participants, interventions, and outcomes. We assessed risk of bias of studies with the Cochrane risk of bias tool and the certainty of the evidence using the GRADE approach. We presented results using risk ratios (RR) and 95% confidence intervals (CI) when meta‐analysis was possible. All other results are presented in a narrative synthesis. </p> </section> <section id="CD013437-sec-0006"> <h3 class="title" id="CD013437-sec-0006">Main results</h3> <p>We found that five different adjuvant therapies have been tested in RCTs for bacterial meningitis. These include paracetamol (3 studies, 1274 participants who were children); immunoglobulins (2 studies, 49 participants; one study included children, and the other adults); heparin (1 study, 15 participants who were adults); pentoxifylline (1 study, 57 participants who were children); and a mixture of succinic acid, inosine, nicotinamide, and riboflavin mononucleotide (1 study, 30 participants who were children). Paracetamol may make little or no difference to mortality (paracetamol 35.2% versus placebo 37.4%, 95% CI 30.3% to 40.8%; RR 0.94, 95% CI 0.81 to 1.09; 3 studies, 1274 participants; I² = 0%; low certainty evidence); hearing loss (RR 1.04, 95% CI 0.80 to 1.34; 2 studies, 901 participants; I² = 0%; low certainty evidence); neurological sequelae other than hearing loss (RR 1.56, 95% CI 0.98 to 2.50; 3 studies, 1274 participants; I² = 60%; low certainty evidence); and severe hearing loss (RR 0.96, 95% CI 0.67 to 1.36; 2 studies, 901 participants; I² = 0%; low certainty evidence). Paracetamol may lead to slightly more short‐term neurological sequelae other than hearing loss (RR 1.99, 95% CI 1.40 to 2.81; 2 studies, 1096 participants; I² = 0%; low certainty evidence) and slightly more long‐term neurological sequelae other than hearing loss (RR 2.32, 95% CI 1.34 to 4.04; 2 studies, 901 participants; I² = 0%; low certainty evidence). No adverse events were reported in either group in any of the paracetamol studies (very low certainty evidence). Two paracetamol studies had a low risk of bias in most domains, and one had low or unclear risk of bias in all domains. We judged the certainty of evidence to be low for mortality due to limitations in study design (unclear risk of bias in at least one domain and imprecision (high level of uncertainty in absolute effects), and low for all other outcomes due to limitations in study design (unclear risk of bias in at least one domain), and imprecision (low sample size and few events) or inconsistency in effect estimates (heterogeneity). </p> <p>We were not able to perform meta‐analysis for any of the other adjuvant therapies due to the limited number of included studies. It is uncertain whether immunoglobulins, heparin, or pentoxifylline improves mortality outcomes due to the very low certainty of the evidence. Zero adverse events were reported for immunoglobulins (very low certainty evidence), and allergic reactions occurred at a rate of 3.3% in participants receiving a mixture of succinic acid, inosine, nicotinamide, and riboflavin mononucleotide (intervention group) (very low certainty evidence). None of our other outcomes (hearing loss, neurological sequelae other than hearing loss, severe hearing loss, and short‐term or long‐term neurological sequelae other than hearing loss) were reported in these studies, and all of these studies were judged to have a high risk of bias. All reported outcomes for all included adjuvant therapies, other than paracetamol, were graded as very low certainty of evidence due to limitations in study design (unclear or high risk of bias in at least four domains) and imprecision (extremely low sample size and few events). </p> </section> <section id="CD013437-sec-0007"> <h3 class="title" id="CD013437-sec-0007">Authors' conclusions</h3> <p>Few adjuvant therapies for bacterial meningitis have been tested in RCTs. Paracetamol may make little or no difference to mortality, with a high level of uncertainty in the absolute effects (low certainty evidence). Paracetamol may make little or no difference to hearing loss, neurological sequelae other than hearing loss, and severe hearing loss (all low certainty evidence). Paracetamol may lead to slightly more short‐term and long‐term neurological sequelae other than hearing loss (both outcomes low certainty evidence). There is insufficient evidence to determine whether any of the adjuvant therapies included in this review (paracetamol, immunoglobulins, heparin, pentoxifylline, or a mixture of succinic acid, inosine, nicotinamide, and riboflavin mononucleotide) are beneficial or detrimental in acute bacterial meningitis. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013437-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013437-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013437-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013437-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013437-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013437-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013437-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013437-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013437-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013437-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013437-abs-0002" lang="en"> <h3>Non‐corticosteroid adjuvant therapies for bacterial meningitis</h3> <p><b>Review question</b> </p> <p>We wanted to find out if adjuvant therapies (therapies used in addition to standard treatment methods) other than corticosteroids (a type of anti‐inflammatory drug) are better or worse than standard treatment (antibiotics, used with or without corticosteroids) alone or with a placebo (dummy treatment) in treating people with acute bacterial meningitis (a bacterial infection of the membranes that surround and protect the brain). To answer this question, we reviewed the available evidence on the effect of adjuvant therapies other than corticosteroids on death, hearing loss, and other neurological sequelae (aftereffects of a disease) in people with acute bacterial meningitis. </p> <p><b>Background</b> </p> <p>Acute bacterial meningitis is an infection of the protective membranes that surround the brain, known as the meninges. Meningitis causes inflammation and damage to the brain tissue, leading to death in 7% to 50% of cases. Survivors often have neurological sequelae (neurological symptoms that persist after the infection is cured, such as hearing loss, physical disability (impairment), localised problems (focal neurological deficits, or loss of normal function of brain, spinal cord, or nerves that is localised to a specific area of the body), seizures, and cognitive impairment, which often lead to learning difficulties in children and trouble returning to work for adults) that can last for weeks to years. Bacterial meningitis is treated with antibiotics as the primary therapy, with corticosteroids the only recommended adjuvant therapy that has been shown to improve outcomes. We wanted to find out whether the use of adjuvant therapies other than corticosteroids is better or worse than standard treatment alone or with a placebo in people with acute bacterial meningitis. </p> <p><b>Search date</b> </p> <p>The evidence is current to September 2021.</p> <p><b>Study characteristics</b> </p> <p>We assessed all adjuvant pharmacological (drug) therapies (except corticosteroids) for which we found randomised controlled trials (a type of study where participants are randomly assigned to one of two or more treatment groups) conducted in people with acute bacterial meningitis. We found eight studies examining five different interventions. </p> <p>Three studies (1274 participants) evaluated paracetamol in children (excluding newborns) with bacterial meningitis. The studies were funded by government funding organisations and research foundations. One study additionally reported funding support from a daily newspaper, and one study reported funding support from a pharmaceutical company. </p> <p>Two studies (49 participants) evaluated immunoglobulins in bacterial meningitis. One study included children (excluding newborns), whilst the other study included adults of unspecified age. Funding sources were not specified. One study received the study medication from a pharmaceutical company. </p> <p>One study (15 participants) evaluated heparin (blood thinner) in adults with bacterial meningitis. The study was funded by a research foundation. </p> <p>One study (57 participants) evaluated pentoxifylline in children (excluding newborns) with bacterial meningitis. Funding sources for the study were not specified. </p> <p>One study (30 participants) evaluated a mixture of succinic acid, inosine, nicotinamide, and riboflavin mononucleotide in children (excluding newborns). Funding sources for the study were not specified. </p> <p><b>Key results</b> </p> <p>We found that paracetamol may make little or no difference for the number of deaths (paracetamol 35.2% (potentially causing between 7.1% fewer deaths up to 3.4% more deaths) versus placebo 37.4%, low certainty evidence). Paracetamol may make little to no difference in hearing loss (paracetamol 19.6% versus placebo 18.8%, low certainty evidence); neurological sequelae other than hearing loss (paracetamol 32.1% versus placebo 20.6%, low certainty evidence); or severe hearing loss (paracetamol 11.7% versus placebo 12.2%, low certainty evidence). Paracetamol may lead to slightly more short‐term neurological sequelae other than hearing loss (paracetamol 15.7% versus placebo 7.9%, low certainty evidence) and slightly more long‐term neurological sequelae other than hearing loss (paracetamol 8.8% versus placebo 3.8%, low certainty evidence). No side effects were reported. </p> <p>The effect of immunoglobulins, heparin, pentoxifylline, and a mixture of succinic acid, inosine, nicotinamide, and riboflavin mononucleotide on number of deaths is uncertain due to the very low certainty of the evidence. No side effects were reported for immunoglobulins (very low certainty evidence), and a 3.3% rate of allergic reactions was reported in patients receiving a mixture of succinic acid, inosine, nicotinamide, and riboflavin mononucleotide (intervention group) (very low certainty evidence). None of our other outcomes (hearing loss, neurological sequelae other than hearing loss, severe hearing loss, and short‐term or long‐term neurological sequelae other than hearing loss) were reported in these studies. </p> <p><b>Certainty of the evidence</b> </p> <p>The certainty of evidence for paracetamol was low for all outcomes due to issues with study design, inconsistency of results and too few participants in the studies and sparse reporting of the outcomes of interest for this review. The certainty of evidence was very low for all other treatments due to issues with study design and not enough data. No conclusions could be drawn about the effectiveness of any of the evaluated treatments at this time because of the limited and low certainty of the evidence. This may change if results from larger studies with improved design become available. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013437-sec-0116" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013437-sec-0116"></div> <h3 class="title" id="CD013437-sec-0117">Implications for practice</h3> <section id="CD013437-sec-0117"> <p>The available evidence is insufficient to determine the effects of paracetamol in bacterial meningitis. Our meta‐analysis showed that paracetamol may make little or no difference to mortality (low‐certainty evidence), with a high level of uncertainty with regard to absolute effects, and may make little or no difference to hearing loss (low‐certainty evidence). Paracetamol may lead to slightly more short‐ and long‐term neurological sequelae in bacterial meningitis in children (low‐certainty evidence). Uncontrolled fever can also lead to neurological sequelae and seizures, and paracetamol is currently an important part of fever control. In the included studies, paracetamol was used regardless of fever or the general condition of the patient upon arrival. The results may therefore not be generalisable to the clinical setting where paracetamol is used primarily for high fever and pain. </p> <p>Due to the limited number of studies addressing other interventions and the very low certainty of the available evidence, it is uncertain what effects immunoglobulins, heparin, pentoxifylline, and a mixture of succinic acid, inosine, nicotinamide, and riboflavin mononucleotide have in acute bacterial meningitis in children or adults. </p> </section> <h3 class="title" id="CD013437-sec-0118">Implications for research</h3> <section id="CD013437-sec-0118"> <p>This review indicates that there is a paucity of evidence for or against any non‐corticosteroid adjuvant pharmacological therapies in acute bacterial meningitis. The most well‐tested therapy that we identified is paracetamol, and low certainty evidence indicates that it may lead to slightly more short‐long term neurological sequelae in children; however, the biological mechanism for this effect is unclear. Given the low certainty of the evidence, further high‐quality studies may be needed. Additionally, these outcomes may be regarded as hypothesis‐generating and could serve as inspiration for the design of future studies. If further clinical studies are conducted, they should focus on the specific subgroup of patients with bacterial meningitis and fever. </p> <p>All other interventions had few studies with small numbers of participants, therefore the certainty of the evidence obtained from them is very low. The overall lack of high‐quality studies of non‐corticosteroid pharmacological adjuvant therapies in bacterial meningitis indicates that there is a need for more pre‐clinical research to identify potential candidate therapeutics for future clinical trials and a need for large, high‐quality trials focusing on relevant clinical outcomes to test promising new non‐corticosteroid adjuvant therapies in the future. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013437-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013437-sec-0008"></div> <div class="table" id="CD013437-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Paracetamol for acute bacterial meningitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Paracetamol for acute bacterial meningitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with acute bacterial meningitis<br/><b>Settings:</b> hospitals in Malawi and Angola<br/><b>Intervention:</b> paracetamol<br/><b>Comparison:</b> standard treatment plus paracetamol versus standard treatment plus placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Paracetamol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p><i>during the follow‐up period</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>374 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>352 per 1000</b><br/>(303 to 408) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/>(0.81 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1274 children<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any hearing loss</b> </p> <p><i>defined as 40 dB or more not detected by the better ear during the follow‐up period</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>188 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>196 per 1000</b><br/>(150 to 252) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> <br/>(0.8 to 1.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>901 children<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any neurological sequelae other than hearing loss</b> </p> <p><i>defined as health consequences of the infection that involve the central nervous system during the follow‐up period. Can include seizure disorder, focal neurological deficit, ataxia, paresis, or psychomotor retardation</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>206 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>321 per 1000</b><br/>(202 to 515) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.56</b> <br/>(0.98 to 2.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1274 children<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p><i>during the follow‐up period</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1274 children<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe hearing loss</b> </p> <p><i>defined as a threshold of 60 dB or more in the better ear or requiring bilateral hearing aid during the follow‐up period</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>122 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>117 per 1000</b><br/>(82 to 166) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> <br/>(0.67 to 1.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>901 children<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term neurological sequelae other than hearing loss</b> </p> <p><i>defined as sequelae present up to 6 weeks after hospital discharge</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>79 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>157 per 1000</b><br/>(111 to 222) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.99</b> <br/>(1.4 to 2.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1096 children<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Long‐term neurological sequelae other than hearing loss</b> </p> <p><i>defined as sequelae present between 6 weeks after hospital discharge and the last time point reported in the study</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>88 per 1000</b><br/>(51 to 154) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.32</b> <br/>(1.34 to 4.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>901 children<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>dB:</b> decibels; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Limitations in study design: downgraded by one level due to included study at unclear risk of bias in at least one domain.<br/><sup>b</sup>Imprecision: downgraded by one level due to high level of uncertainty in the absolute effects.<br/><sup>c</sup>Imprecision: downgraded by one level due to extremely low sample size and few events.<br/><sup>d</sup>Consistency of effect: downgraded by one level for inconsistency in effect estimates (moderate or high heterogeneity, I² &gt; 50%).<br/><sup>e</sup>Imprecision: downgraded by two levels due to extremely low sample size and no events. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013437-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013437-sec-0009"></div> <section id="CD013437-sec-0010"> <h3 class="title" id="CD013437-sec-0010">Description of the condition</h3> <p>Acute bacterial meningitis is a bacterial infection of the membranes that surround and protect the brain, known as the meninges. Because of the low permeability of the blood‐brain barrier, the brain does not normally come in contact with bacteria or immune cells (<a href="./references#CD013437-bbs2-0068" title="Van SorgeNM , DoranKS . Defense at the border: the blood–brain barrier versus bacterial foreigners. Future Microbiology2012;7(3):383-94.">Van Sorge 2012</a>), but when it does, an infection in the brain can have devastating effects. Acute bacterial meningitis causes inflammation, thrombosis (blood clots), and oedema (swelling) in the brain which can lead to significant damage to the brain tissue (<a href="./references#CD013437-bbs2-0044" title="HoffmanO , WeberRJ . Pathophysiology and treatment of bacterial meningitis. Therapeutic Advances in Neurological Disorders2009;2(6):401-12.">Hoffman 2009</a>; <a href="./references#CD013437-bbs2-0051" title="LucasMJ , BrouwerMC , vande BeekD . Neurological sequelae of bacterial meningitis. Journal of Infection2016;73(1):18-27.">Lucas 2016</a>). </p> <p>Globally, meningitis had a prevalence of 10.5 million cases in 2017 and caused over 288,000 deaths (<a href="./references#CD013437-bbs2-0040" title="Global Burden of Disease 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet2018;392:1789–858.">GBD Study 2017</a>). In spite of timely antibiotic treatment and improvements in intensive care, the mortality rate of acute bacterial meningitis (which varies widely between studies) is reported to be around 7% to 23% in high‐income countries depending on age and pathogen (<a href="./references#CD013437-bbs2-0030" title="BijlsmaMW , BrouwerMC , KasanmoentalibES , KloekAT , LucasMJ , TanckMW , et al. Community-acquired bacterial meningitis in adults in the Netherlands, 2006–14: a prospective cohort study. Lancet Infectious Diseases2016;16(3):339-47.">Bijlsma 2016</a>; <a href="./references#CD013437-bbs2-0036" title="deGansJ , vande BeekD . Dexamethasone in adults with bacterial meningitis. New England Journal of Medicine2002;347(20):1549-56.">deGans 2002</a>; <a href="./references#CD013437-bbs2-0064" title="SharewA , BodilsenJ , HansenBR , NielsenH , BrandtCT . The cause of death in bacterial meningitis. BMC Infectious Diseases2020;20:182.">Sharew 2020</a>), rising to more than 50% in low‐income countries (<a href="./references#CD013437-bbs2-0055" title="NguyenTH , TranTH , ThwaitesG , LyVC , DinhXS , Ho DangTN , et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. New England Journal of Medicine2007;357(24):2431-40.">Nguyen 2007</a>; <a href="./references#CD013437-bbs2-0063" title="ScarboroughM , GordonSB , WhittyCJ , FrenchN , NjalaleY , ChitaniA , et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. New England Journal of Medicine2007;357(24):2441-50.">Scarborough 2007</a>; <a href="./references#CD013437-bbs2-0070" title="WallEC , CartwrightK , ScarboroughM , AjdukiewiczKM , GoodsonP , MwambeneJ , et al. High mortality amongst adolescents and adults with bacterial meningitis in sub-Saharan Africa: an analysis of 715 cases from Malawi. PLOS ONE2013;8(7):e69783.">Wall 2013</a>). Rates of acute bacterial meningitis also tend to be highest in low‐income countries (<a href="./references#CD013437-bbs2-0065" title="vande BeekD , BrouwerM , HasbunR , KoedelU , WhitneyCG , WijdicksE . Community-acquired bacterial meningitis. Nature Reviews Disease Primers2016;2:16074.">van de Beek 2016a</a>). </p> <p>Survivors of acute bacterial meningitis often develop neurological sequelae (neurological symptoms that persist after the infection is cured) such as hearing loss, physical impairment, focal neurological deficits, seizures, and cognitive impairment. Some neurologic sequelae improve over time, whilst others are permanent (<a href="./references#CD013437-bbs2-0051" title="LucasMJ , BrouwerMC , vande BeekD . Neurological sequelae of bacterial meningitis. Journal of Infection2016;73(1):18-27.">Lucas 2016</a>). Neurologic sequelae lead to learning difficulties in children and trouble returning to work for adults, and therefore have an important socioeconomic impact (<a href="./references#CD013437-bbs2-0051" title="LucasMJ , BrouwerMC , vande BeekD . Neurological sequelae of bacterial meningitis. Journal of Infection2016;73(1):18-27.">Lucas 2016</a>; <a href="./references#CD013437-bbs2-0059" title="PickeringL , JennumP , IbsenR , KjellbergJ . Long-term health and socioeconomic consequences of childhood and adolescent onset of meningococcal meningitis. European Journal of Pediatrics2018;177(9):1309-15.">Pickering 2018</a>). Consequently, it is important to reduce both the mortality and neurological sequelae of acute bacterial meningitis. One strategy for reduction of adverse outcomes in acute bacterial meningitis is the development and testing of new adjuvant therapies. </p> </section> <section id="CD013437-sec-0011"> <h3 class="title" id="CD013437-sec-0011">Description of the intervention</h3> <p>The primary therapy used in bacterial meningitis is antibiotic treatment, whilst adjuvant therapies are given in addition to the primary therapy to improve effectiveness or reduce adverse effects, or both. The only adjuvant pharmacological therapy currently recommended for acute bacterial meningitis is corticosteroids (<a href="./references#CD013437-bbs2-0066" title="vande BeekD , CabellosC , DzupovaO , EspositoS , KleinM , KloekAT , et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clinical Microbiology and Infection2016;22(Suppl 3):37-62.">van de Beek 2016b</a>; <a href="./references#CD013437-bbs2-0067" title="vanEttekovenCN , vande BeekD , BrouwerMC . Update on community-acquired bacterial meningitis: guidance and challenges. Clinical Microbiology and Infection2017;23(9):601-6.">van Ettekoven 2017</a>). Evidence for this recommendation comes largely from a 2015 Cochrane Review (<a href="./references#CD013437-bbs2-0034" title="BrouwerMC , McIntyreP , PrasadK , vande BeekD . Corticosteroids for acute bacterial meningitis. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD004405. [DOI: 10.1002/14651858.CD004405.pub5]">Brouwer 2015</a>), which indicates that corticosteroids significantly decrease rates of hearing loss and neurological sequelae in acute bacterial meningitis, but have no significant effect on mortality overall. Additionally, corticosteroid therapy has no benefits in low‐income regions (<a href="./references#CD013437-bbs2-0034" title="BrouwerMC , McIntyreP , PrasadK , vande BeekD . Corticosteroids for acute bacterial meningitis. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD004405. [DOI: 10.1002/14651858.CD004405.pub5]">Brouwer 2015</a>), which have the highest incidence of acute bacterial meningitis (<a href="./references#CD013437-bbs2-0032" title="BrouwerMC , TunkelAR , vande BeekD . Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clinical Microbiology Reviews2010;23(3):467-92.">Brouwer 2010a</a>). There is clearly room for improvement in the effectiveness of the available treatments for acute bacterial meningitis. </p> <p>Several other adjuvant pharmacological therapies have been explored in randomised controlled trials (RCTs), including paracetamol (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>), immunoglobulins (<a href="./references#CD013437-bbs2-0004" title="NeuIS , PelkaRB . Immunoglobulins in bacterial and viral meningitis. Results of a controlled randomized clinical study of intravenous and intrathecal application. Fortschritte der Medizin1982;100(17):802-9. ">Neu 1982</a>), and heparin (<a href="./references#CD013437-bbs2-0001" title="MacFarlaneJT , ClelandPG , AttaiED , GreenwoodBM . Failure of heparin to alter the outcome of pneumococcal meningitis. BMJ1977;2(6101):1522. ">MacFarlane 1977</a>). We assessed all RCTs of adjuvant pharmacological therapies (except corticosteroids) conducted in people with acute bacterial meningitis. The included interventions were adjuvant to antibiotics, but it was possible that they would also occur in combination with corticosteroids due to their common use as an adjuvant therapy. </p> </section> <section id="CD013437-sec-0012"> <h3 class="title" id="CD013437-sec-0012">How the intervention might work</h3> <p>We assessed several different pharmacological treatments in this review; the mode of action therefore depends on the specific intervention. Some possible treatments were paracetamol, immunoglobulins, and heparin. </p> <section id="CD013437-sec-0013"> <h4 class="title">Paracetamol</h4> <p>Paracetamol is commonly taken to relieve pain and fever. Although it is not typically considered an anti‐inflammatory drug (<a href="./references#CD013437-bbs2-0028" title="AronoffDM , OatesJA , BoutaudO . New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clinical Pharmacology and Therapeutics2006;79(1):9-19.">Aronoff 2006</a>), it may have some mild anti‐inflammatory and antioxidant effects (<a href="./references#CD013437-bbs2-0031" title="BloughER , WuM . Acetaminophen: beyond pain and fever-relieving. Frontiers in Pharmacology2011;2:72. [DOI: 10.3389/fphar.2011.00072]">Blough 2011</a>). Retrospective analyses of people with bacteraemia indicated that they had a reduced risk of death when given paracetamol (<a href="./references#CD013437-bbs2-0045" title="KuikkaA , SivonenA , EmelianovaA , ValtonenVV . Prognostic factors associated with improved outcome of Escherichia coli bacteremia in a Finnish university hospital. European Journal of Clinical Microbiology &amp; Infectious Diseases1997;16(2):125-34.">Kuikka 1997</a>; <a href="./references#CD013437-bbs2-0046" title="KuikkaA , ValtonenVV . Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. European Journal of Clinical Microbiology &amp; Infectious Diseases1998;17(10):701-8.">Kuikka 1998</a>). This result was the basis for clinical trials evaluating paracetamol as an adjunctive therapy in acute bacterial meningitis (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>). Paracetamol may be neuroprotective by reducing fever or by its anti‐inflammatory and antioxidant properties (<a href="./references#CD013437-bbs2-0028" title="AronoffDM , OatesJA , BoutaudO . New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clinical Pharmacology and Therapeutics2006;79(1):9-19.">Aronoff 2006</a>; <a href="./references#CD013437-bbs2-0031" title="BloughER , WuM . Acetaminophen: beyond pain and fever-relieving. Frontiers in Pharmacology2011;2:72. [DOI: 10.3389/fphar.2011.00072]">Blough 2011</a>). </p> </section> <section id="CD013437-sec-0014"> <h4 class="title">Immunoglobulins</h4> <p>Intravenous immunoglobulin (IVIg) therapy involves administering immunoglobulins intravenously. Immunoglobulins are immune proteins taken from healthy human blood. IVIg is beneficial in some conditions, although its specific mode of action is unclear (<a href="./references#CD013437-bbs2-0058" title="PerezEE , OrangeJS , BonillaF , ChinenJ , ChinnIK , DorseyM , et al. Update on the use of immunoglobulin in human disease: a review of evidence. Journal of Allergy and Clinical Immunology2017;139(3):S1-46.">Perez 2017</a>). During infections, IVIg can provide antibodies that help the immune system to neutralise bacteria, and can interfere with the effects of proinflammatory molecules known as cytokines. However, IVIg has not shown clear benefits in sepsis and septic shock (<a href="./references#CD013437-bbs2-0027" title="AlejandriaMM , LansangMA , DansLF , Mantaring JB 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database of Systematic Reviews2013, Issue 9. Art. No: CD001090. [DOI: 10.1002/14651858.CD001090.pub2]">Alejandria 2013</a>). In acute bacterial meningitis, immunoglobulin preparations were administered both intravenously and intrathecally (by injection into the spinal canal or into the subarachnoid space in order to reach the cerebrospinal fluid) in one RCT, <a href="./references#CD013437-bbs2-0004" title="NeuIS , PelkaRB . Immunoglobulins in bacterial and viral meningitis. Results of a controlled randomized clinical study of intravenous and intrathecal application. Fortschritte der Medizin1982;100(17):802-9. ">Neu 1982</a>, and in one non‐randomised trial that used a historical cohort as the control group (<a href="./references#CD013437-bbs2-0018" title="NoackR , SzugsC , ScholzH . Immunoglobulins in the treatment of bacterial meningitis in childhood [Immunglobuline bei der Behandlung der bakteriellen Meningitisim Kindesalter]. Infection1987;15(1):11-5. ">Noack 1987</a>). </p> </section> <section id="CD013437-sec-0015"> <h4 class="title">Heparin</h4> <p>Heparin and heparin‐based drugs are commonly used as anticoagulants, preventing blood clot formation (<a href="./references#CD013437-bbs2-0057" title="OnishiA , St Ange K, DordickJS , LinhardtRJ . Heparin and anticoagulation. Frontiers in Bioscience (Landmark edition)2016;21:1372-92.">Onishi 2016</a>). During bacterial meningitis, blood clots may form in the blood vessels of the brain, known as cerebral vascular thrombosis (<a href="./references#CD013437-bbs2-0044" title="HoffmanO , WeberRJ . Pathophysiology and treatment of bacterial meningitis. Therapeutic Advances in Neurological Disorders2009;2(6):401-12.">Hoffman 2009</a>; <a href="./references#CD013437-bbs2-0051" title="LucasMJ , BrouwerMC , vande BeekD . Neurological sequelae of bacterial meningitis. Journal of Infection2016;73(1):18-27.">Lucas 2016</a>). Because heparin can prevent blood clot formation, it has been proposed that heparin treatment may reduce cerebral vascular thrombosis. This provided the basis for an RCT of heparin in acute bacterial meningitis (<a href="./references#CD013437-bbs2-0001" title="MacFarlaneJT , ClelandPG , AttaiED , GreenwoodBM . Failure of heparin to alter the outcome of pneumococcal meningitis. BMJ1977;2(6101):1522. ">MacFarlane 1977</a>). Heparin is also known to have anti‐inflammatory and immunomodulatory effects, which has led to interest in its use as a treatment in severe infections. However, its tendency to cause bleeding complications could preclude its use as a treatment (<a href="./references#CD013437-bbs2-0050" title="LiX , MaX . The role of heparin in sepsis: much more than just an anticoagulant. British Journal of Haematology2017;179(3):389-98.">Li 2017</a>). </p> </section> </section> <section id="CD013437-sec-0016"> <h3 class="title" id="CD013437-sec-0016">Why it is important to do this review</h3> <p>Several systematic reviews have been conducted to assess various adjuvant therapies for acute bacterial meningitis. These therapies include corticosteroids in adults, <a href="./references#CD013437-bbs2-0034" title="BrouwerMC , McIntyreP , PrasadK , vande BeekD . Corticosteroids for acute bacterial meningitis. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD004405. [DOI: 10.1002/14651858.CD004405.pub5]">Brouwer 2015</a>, and in neonates (<a href="./references#CD013437-bbs2-0056" title="OgunlesiTA , OdigweCC , OladapoOT . Adjuvant corticosteroids for reducing death in neonatal bacterial meningitis. Cochrane Database of Systematic Reviews2015, Issue 11. Art. No: CD010435. [DOI: 10.1002/14651858.CD010435.pub2]">Ogunlesi 2015</a>); osmotic therapies (<a href="./references#CD013437-bbs2-0071" title="WallEC , AjdukiewiczKM , BergmanH , HeydermanRS , GarnerP . Osmotic therapies added to antibiotics for acute bacterial meningitis. Cochrane Database of Systematic Reviews2018, Issue 2. Art. No: CD008806. [DOI: 10.1002/14651858.CD008806.pub2]">Wall 2018</a>); and fluid therapy (<a href="./references#CD013437-bbs2-0052" title="MaconochieIK , BhaumikS . Fluid therapy for acute bacterial meningitis. Cochrane Database of Systematic Reviews2016, Issue 11. Art. No: CD004786. [DOI: 10.1002/14651858.CD004786.pub5]">Maconochie 2016</a>). However, there exist RCTs for several adjuvant pharmacological therapies, as described above, that have not yet been assessed in a systematic review. To avoid overlap with previous Cochrane Reviews, we examined the effectiveness of all existing pharmacological adjuvant therapies for acute bacterial meningitis, excluding corticosteroids. Pharmacological therapies were defined as treatments that are expected to act on a specific target or receptor, and so our review also excluded osmotic therapies. This review is important in determining whether there is sufficient evidence to guide the clinical use of any such therapies. The review also highlights gaps in the available research, so that future clinical trial efforts can focus on those therapies which are most promising, or those for which further evidence is needed. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013437-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013437-sec-0017"></div> <p>To assess the effects of non‐corticosteroid adjuvant pharmacological therapies for mortality, hearing loss, and other neurological sequelae in people with acute bacterial meningitis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013437-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013437-sec-0018"></div> <section id="CD013437-sec-0019"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013437-sec-0020"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs). We included studies reported as full text, those published as abstract only, and unpublished data. </p> </section> <section id="CD013437-sec-0021"> <h4 class="title">Types of participants</h4> <p>We included people of any age with a diagnosis of acute bacterial meningitis, caused by any bacterial pathogen, as confirmed by a physician. In studies in which only a subset of people have acute bacterial meningitis (e.g. studies that include multiple diseases such as viral meningitis), we included data only for the subset of people with acute bacterial meningitis. </p> </section> <section id="CD013437-sec-0022"> <h4 class="title">Types of interventions</h4> <p>We included trials with any non‐corticosteroid pharmacological therapy adjuvant to the standard treatment compared to the standard treatment alone or with placebo. We included any dose, route of administration, and duration of therapy. We compared each intervention included in this review separately. </p> <p>Adjuvant therapies are treatments given in addition to the primary therapy. The primary therapy in bacterial meningitis is antibiotic treatment. </p> <p>Pharmacological therapies were defined as those treatments that are expected to act on a specific target or receptor, therefore osmotic therapies were excluded from the review. We clarified our inclusion criteria to specify that we would not include pharmacological therapies whose primary function as an adjuvant therapy is to alter pharmacokinetics of antibiotics. </p> <p>Standard treatment was defined as any antibiotic (regardless of route of administration) and any concomitant treatments (such as corticosteroids), provided that these concomitant treatments were not randomised. </p> </section> <section id="CD013437-sec-0023"> <h4 class="title">Types of outcome measures</h4> <section id="CD013437-sec-0024"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013437-list-0001"> <li> <p>All‐cause mortality during the follow‐up period.</p> </li> <li> <p>Any hearing loss (defined as 40 decibels (dB) or more not detected by the better ear). At this threshold, understanding of speech is partially lost, and difficulty in understanding conversation is noticeable (<a href="./references#CD013437-bbs2-0037" title="DixMR , HallpikeCS . The peep show: a new technique for pure-tone audiometry in young children. BMJ1947;2(4531):719-23.">Dix 1947</a>). </p> </li> <li> <p>Any neurological sequelae other than hearing loss. Neurological sequelae are defined as health consequences of the infection that involve the central nervous system. These can include seizure disorder, focal neurological deficit (loss of normal function of brain, spinal cord, or nerves that is localised to a specific area of the body), ataxia (loss of voluntary co‐ordination of muscle movement), paresis (partial paralysis or muscle weakness), or psychomotor retardation (slowing of thought and reduction of physical movements). </p> </li> <li> <p>Adverse effects attributed to the intervention.</p> </li> </ol> </p> </section> <section id="CD013437-sec-0025"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013437-list-0002"> <li> <p>Severe hearing loss (defined as a threshold of 60 dB or more in the better ear or requiring bilateral hearing aid). At this threshold, the understanding of normal conversation is severely impaired (<a href="./references#CD013437-bbs2-0037" title="DixMR , HallpikeCS . The peep show: a new technique for pure-tone audiometry in young children. BMJ1947;2(4531):719-23.">Dix 1947</a>). </p> </li> <li> <p>Short‐term neurological sequelae other than hearing loss (defined as sequelae present up to six weeks after hospital discharge). </p> </li> <li> <p>Long‐term neurological sequelae other than hearing loss (defined as sequelae present between six weeks after hospital discharge to the last time point reported in the study). </p> </li> </ol> </p> <p>We compared all outcomes for each intervention separately. Reporting one of more of the listed outcomes in the trial was not an inclusion criterion for the review. </p> </section> </section> </section> <section id="CD013437-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013437-sec-0027"> <h4 class="title">Electronic searches</h4> <p>We used the criteria and standard methods of Cochrane. We searched the following databases from their inception. </p> <p> <ol id="CD013437-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (via Wiley) (2021, Issue 9), searched 30 September 2021. </p> </li> <li> <p>MEDLINE (via EBSCO) 1946 to 30 September 2021.</p> </li> <li> <p>Embase (via Elsevier) 1974 to 30 September 2021.</p> </li> <li> <p>CINAHL (via EBSCO) (Cumulative Index to Nursing and Allied Health Literature) 1982 to 30 September 2021. </p> </li> <li> <p>LILACS (via the Virtual Health Library) (Latin American and Caribbean Health Sciences Literature database) 1982 to 30 September 2021. </p> </li> </ol> </p> <p>We used the search strategy described in <a href="./appendices#CD013437-sec-0122">Appendix 1</a>, developed with the aid of a dedicated Information Specialist, to search MEDLINE. We combined the MEDLINE search with the Cochrane Highly Sensitive Search Strategy for randomised trials: sensitivity and precision‐maximising version (2008 revision) (<a href="./references#CD013437-bbs2-0048" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Lefebvre 2021</a>). We used the following search strategies for the other databases: Embase (<a href="./appendices#CD013437-sec-0123">Appendix 2</a>), CENTRAL (<a href="./appendices#CD013437-sec-0124">Appendix 3</a>), CINAHL (<a href="./appendices#CD013437-sec-0125">Appendix 4</a>), and LILACS (<a href="./appendices#CD013437-sec-0126">Appendix 5</a>). </p> <p>We also conducted a search of Clinical Trials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.clinicaltrials.gov</a>) (30 September 2021) and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) (30 September 2021) using the search strategy in <a href="./appendices#CD013437-sec-0127">Appendix 6</a>. We did not impose language or publication restrictions. </p> </section> <section id="CD013437-sec-0028"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all primary studies and review articles for additional references. We reviewed relevant conference proceedings and systematic reviews. We contacted experts in the field to identify additional unpublished materials. </p> </section> </section> <section id="CD013437-sec-0029"> <h3 class="title" id="CD013437-sec-0029">Data collection and analysis</h3> <section id="CD013437-sec-0030"> <h4 class="title">Selection of studies</h4> <p>Two review authors (JF, PB) independently screened the titles and abstracts of all the studies identified as a result of the search for potential relevance. We retrieved the full‐text study reports/publication of those studies deemed potentially relevant, and two review authors (JF, PB) independently screened the full texts and identified studies for inclusion, and identified and recorded reasons for exclusion of the ineligible studies. Any disagreements were resolved through discussion or by consulting a third review author (AL) when required. We identified and excluded duplicate studies and collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and <a href="./references#CD013437-sec-0144" title="">Characteristics of included studies</a> table (<a href="./references#CD013437-bbs2-0053" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. BMJ2009;339:2535. [DOI: 10.1136/bmj.b2535]">Moher 2009</a>). We did not impose any language restrictions. If details of the primary trials were not clear, we contacted the trial authors for clarification. </p> </section> <section id="CD013437-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form for study characteristics and outcome data that was piloted on at least one study in the review. Two review authors (JF, MGC) independently extracted study characteristics from the included studies. We extracted the following study characteristics. </p> <p> <ol id="CD013437-list-0004"> <li> <p>Methods: study design, total duration of study, details of any 'run in' period, number of study centres and location, study setting, withdrawals, and date of study. </p> </li> <li> <p>Participants: N, mean age, age range, gender, severity of condition, diagnostic criteria, inclusion criteria, and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors.</p> </li> </ol> </p> <p>We noted in the <a href="./references#CD013437-sec-0144" title="">Characteristics of included studies</a> table if outcome data were not reported in a useable way. Any disagreements were resolved by consensus or by involving a third review author (PB). One review author (JF) transferred data into Review Manager 5 software (<a href="./references#CD013437-bbs2-0061" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We double‐checked that data were entered correctly by comparing the data presented in the systematic review with the study reports. A second review author (MGC) spot‐checked the study characteristics for accuracy against the trial report. </p> </section> <section id="CD013437-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (JF, MGC) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013437-bbs2-0043" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). Any disagreements were resolved by discussion or by involving another review author (PB). We assessed risk of bias according to the following domains. See <a href="./appendices#CD013437-sec-0128">Appendix 7</a> for detailed information on each risk of bias domain. </p> <p> <ol id="CD013437-list-0005"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ol> </p> <p>We judged each potential source of bias as low, high, or unclear and provided a quote from the study report together with a justification for our judgement in the risk of bias table. We summarised the risk of bias judgements across different studies for each of the domains listed. We considered blinding separately for different key outcomes, where necessary. Where information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the risk of bias table. </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> <section id="CD013437-sec-0033"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to our published protocol and reported any deviations from it in the <a href="#CD013437-sec-0142">Differences between protocol and review</a> section of the review. </p> </section> </section> <section id="CD013437-sec-0034"> <h4 class="title">Measures of treatment effect</h4> <p>We entered the outcome data for each study into the data tables in Review Manager 5 to calculate the treatment effects (<a href="./references#CD013437-bbs2-0061" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We used risk ratios (RRs) and risk differences (RDs) for all outcomes. For each measure of effect we provided the 95% confidence interval (CI). </p> <p>We undertook meta‐analyses only where this was meaningful, that is if the treatments, participants, and the underlying clinical question were similar enough for pooling to make sense. Where applicable, we performed a separate meta‐analysis for each intervention, compared to the control group. </p> </section> <section id="CD013437-sec-0035"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of randomisation was the intended unit of analysis. When studies contained multiple intervention groups that fit our inclusion criteria, we combined groups to make a single comparison as appropriate. </p> </section> <section id="CD013437-sec-0036"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data where possible (e.g. when a study was identified as abstract only). Where this was not possible, and the missing data were thought to introduce serious bias, we would explore the impact of including such studies in the overall assessment of results by a sensitivity analysis. </p> </section> <section id="CD013437-sec-0037"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistic to measure heterogeneity amongst the trials in each analysis (<a href="./references#CD013437-bbs2-0043" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). Additionally, we visually inspected forest plots to guide our assessment of heterogeneity. If we identified substantial heterogeneity, we reported it. There were too few included studies to explore possible causes by prespecified subgroup analysis. </p> <p>We considered the degree of heterogeneity based on the I² statistic as:</p> <p> <ol id="CD013437-list-0006"> <li> <p>less than 25%: no heterogeneity;</p> </li> <li> <p>25% to 49%: low heterogeneity;</p> </li> <li> <p>50% to 74%: moderate heterogeneity;</p> </li> <li> <p>75% or more: high heterogeneity.</p> </li> </ol> </p> <p>We considered statistical heterogeneity to be substantial when the I² statistic value was greater than 50%. </p> </section> <section id="CD013437-sec-0038"> <h4 class="title">Assessment of reporting biases</h4> <p>As we were not able to pool more than 10 trials, we did not create and examine a funnel plot to explore possible small‐study and publication biases. </p> </section> <section id="CD013437-sec-0039"> <h4 class="title">Data synthesis</h4> <p>We pooled data from studies we judged to be clinically homogeneous using Review Manager 5 (<a href="./references#CD013437-bbs2-0061" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). If more than one study provided useable data for any single comparison, we performed a meta‐analysis. </p> <p>In the case of no or low heterogeneity (using the I² statistic and visual inspection of forest plots to guide our judgement), we used a fixed‐effect model for meta‐analysis. If we identified moderate or high heterogeneity amongst studies, we used a random‐effects model. </p> <p>We calculated the risk ratio (RR) and risk difference (RD), each with 95% confidence intervals (CIs). For outcomes where insufficient data were available for meta‐analysis, we have presented a narrative synthesis. </p> </section> <section id="CD013437-sec-0040"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses for each intervention:</p> <p> <ol id="CD013437-list-0007"> <li> <p>participant age: neonate (full term + 28 days), children (aged up to 16 years), and adults (aged over 16 years); </p> </li> <li> <p>low‐income versus high‐income countries; and</p> </li> <li> <p>dose, frequency, and duration of administration of the intervention.</p> </li> </ol> </p> <p>However, the numbers of included studies were insufficient to carry out the planned subgroup analyses. </p> </section> <section id="CD013437-sec-0041"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out the following sensitivity analyses for each intervention:</p> <p> <ol id="CD013437-list-0008"> <li> <p>exclude studies at high risk of bias to ascertain whether such studies overestimate the treatment effect; </p> </li> <li> <p>where a meta‐analysis has been undertaken, use both fixed‐effect and random‐effects models to determine the effect of our choice; and </p> </li> <li> <p>explore the impact of including studies with missing data in the overall assessment of results by comparing an available‐case analysis to a worst‐case scenario analysis. In the latter scenario, we would consider participants with missing data in the intervention group to have an unfavourable outcome, and participants in the control group to have a favourable outcome. </p> </li> </ol> </p> <p>However, the numbers of included studies were insufficient to carry out the planned sensitivity analyses. </p> </section> <section id="CD013437-sec-0042"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created <a href="./full#CD013437-tbl-0001">summary of findings Table 1</a> for all interventions identified, using the following outcomes. </p> <p> <ol id="CD013437-list-0009"> <li> <p>All‐cause mortality during the follow‐up period</p> </li> <li> <p>Any hearing loss</p> </li> <li> <p>Any neurological sequelae other than hearing loss</p> </li> <li> <p>Adverse effects attributed to the intervention</p> </li> <li> <p>Severe hearing loss</p> </li> <li> <p>Short‐term neurological sequelae</p> </li> <li> <p>Long‐term neurological sequelae</p> </li> </ol> </p> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of a body of evidence as it relates to the studies which contribute data to the meta‐analyses for the prespecified outcomes (<a href="./references#CD013437-bbs2-0029" title="AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , et al, GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490.">Atkins 2004</a>). We followed the methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013437-bbs2-0043" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>), employing <a href="./references#CD013437-bbs2-0041" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 11 March 2019. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a> software (<a href="./references#CD013437-bbs2-0041" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 11 March 2019. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). We justified all decisions to down‐ or upgrade the certainty of the evidence using footnotes, and made comments to aid the reader's understanding of the review where necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013437-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013437-sec-0043"></div> <section id="CD013437-sec-0044"> <h3 class="title">Description of studies</h3> <p>For details, see <a href="./references#CD013437-sec-0144" title="">Characteristics of included studies</a>; <a href="./references#CD013437-sec-0145" title="">Characteristics of excluded studies</a>; <a href="./references#CD013437-sec-0146" title="">Characteristics of ongoing studies</a>. </p> <section id="CD013437-sec-0045"> <h4 class="title">Results of the search</h4> <p>The searches of the five databases (see <a href="#CD013437-sec-0027">Electronic searches</a>) retrieved 7158 records. Our searches of other resources identified one additional study that appeared to meet the inclusion criteria. Our searches of the trials registers identified a further 406 studies. Our screening of the reference lists of the included publications revealed one additional record of an included RCT. This resulted in a total of 7565 records, after which 6356 records remained after deduplication. We excluded 6327 records based on title and abstract, and obtained the full texts of the remaining 29 records. We excluded 20 records, 4 of which were duplicates of included study records (see <a href="./references#CD013437-sec-0145" title="">Characteristics of excluded studies</a>). We assessed no studies as awaiting classification. We identified one ongoing study. </p> <p>We included eight studies reported in nine references. A study flow diagram detailing the screening process is provided in <a href="#CD013437-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD013437-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD013437-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD013437-sec-0046"> <h4 class="title">Included studies</h4> <p>The eight included studies evaluated five different interventions: paracetamol, immunoglobulins, heparin, pentoxifylline, and a mixture of succinic acid, inosine, nicotinamide, and riboflavin mononucleotide (<a href="./references#CD013437-sec-0144" title="">Characteristics of included studies</a>). We also identified one study that is listed as ongoing at ClinicalTrials.gov and will test phenytoin (<a href="./references#CD013437-sec-0146" title="">Characteristics of ongoing studies</a>) (<a href="./references#CD013437-bbs2-0025" title="NCT01478035. Study on the efficacy of phenytoin in the prophylaxis of seizures of patients with pneumococcal meningitis at least 50 yrs old [Study on the efficacy of phenytoin in the prophylaxis of seizures of patients with pneumococcal meningitis at least 50 yrs old. A multi-center comparative randomized double-blind and placebo-controlled clinical trial]. clinicaltrials.gov/ct2/show/NCT01478035 (first received 23 November 2011). ">NCT01478035</a>). </p> <p>The studies of paracetamol and pentoxifylline included children. One study of immunoglobulins included children, whilst the other study of immunoglobulins included adults. The study of heparin included adults. Aside from the three paracetamol studies, the numbers of participants in the included studies were small. </p> <section id="CD013437-sec-0047"> <h5 class="title">Paracetamol</h5> <p>Three included studies with a total of 1274 participants evaluated paracetamol compared to a placebo (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>). One of these studies included glycerol arms (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>); one included cefotaxime infusion arms (<a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>); and one compared paracetamol + cefotaxime infusion to a placebo + cefotaxime bolus arm (<a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>). A sample size calculation was given in all studies, and only one study did not achieve the target sample size (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>). </p> <p>One study included participants in Malawi (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>), whilst two studies included participants in Angola (<a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>). All three studies included children at least two months of age up to a maximum of either 13 years (<a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>), 15 years (<a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>), or no upper limit stated (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>). In all three studies, up to one parenteral dose of antibiotic was allowed prior to administration of the randomised treatment. </p> <p>Paracetamol was given at an initial loading dose of 30 mg/kg or 35 mg/kg followed by 20 mg/kg every six hours thereafter. It was given rectally or orally, and duration ranged from 42 hours to 4 days. Placebo was cocoa butter suppository for rectal administration or plain water for oral administration. </p> <p>The primary outcomes in two studies included mortality (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>), whilst the primary outcome in the remaining study was a composite outcome of death or severe neurological sequelae (<a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>). Any hearing loss (hearing threshold &gt; 40 dB) was included as a composite outcome along with death and neurological sequelae in two studies, but not reported alone. Severe hearing loss (threshold &gt; 60 dB) was not reported in any study, but two studies reported deafness (threshold &gt; 80 dB). Definitions of neurological sequelae varied slightly between studies and were reported at hospital discharge in two studies (<a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>), and at an undefined time in one study (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>). We contacted the study authors, and authors of two studies provided additional unpublished data regarding hearing loss and short‐ and long‐term neurological sequelae according to our definitions (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>); we did not receive a response to our request from the authors of the third study (<a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>). </p> <p>All three studies were registered in clinical trial registries prior to study start. One study was funded entirely by a government funding organisation (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>); one by research foundations and a daily newspaper (<a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>); and one study was funded primarily by research foundations, with one author reporting funding support from a pharmaceutical company (<a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>). </p> </section> <section id="CD013437-sec-0048"> <h5 class="title">Immunoglobulins</h5> <p>Two included studies with a total of 49 participants evaluated immunoglobulins compared to standard treatment alone (no placebo) (<a href="./references#CD013437-bbs2-0004" title="NeuIS , PelkaRB . Immunoglobulins in bacterial and viral meningitis. Results of a controlled randomized clinical study of intravenous and intrathecal application. Fortschritte der Medizin1982;100(17):802-9. ">Neu 1982</a>; <a href="./references#CD013437-bbs2-0008" title="SzenbornL , RudowskiZ . Use of immunoglobulin enriched with class IgM antibodies in treatment of purulent meningitis [Zastosowanie immunoglobuliny wzbogaconej w przeciwciała klasy IgM w leczeniu ropnego zapalenia opon mózgowo-rdzeniowych]. Polski Tygodnik lLekarski1994;49(20-2):465-7. ">Szenborn 1994</a>). None of the studies specified the country or institution where participants were enrolled, but presumably the studies took place in Germany, <a href="./references#CD013437-bbs2-0004" title="NeuIS , PelkaRB . Immunoglobulins in bacterial and viral meningitis. Results of a controlled randomized clinical study of intravenous and intrathecal application. Fortschritte der Medizin1982;100(17):802-9. ">Neu 1982</a>, and Poland, <a href="./references#CD013437-bbs2-0008" title="SzenbornL , RudowskiZ . Use of immunoglobulin enriched with class IgM antibodies in treatment of purulent meningitis [Zastosowanie immunoglobuliny wzbogaconej w przeciwciała klasy IgM w leczeniu ropnego zapalenia opon mózgowo-rdzeniowych]. Polski Tygodnik lLekarski1994;49(20-2):465-7. ">Szenborn 1994</a>. One study included children (2 weeks to 16 months) (<a href="./references#CD013437-bbs2-0008" title="SzenbornL , RudowskiZ . Use of immunoglobulin enriched with class IgM antibodies in treatment of purulent meningitis [Zastosowanie immunoglobuliny wzbogaconej w przeciwciała klasy IgM w leczeniu ropnego zapalenia opon mózgowo-rdzeniowych]. Polski Tygodnik lLekarski1994;49(20-2):465-7. ">Szenborn 1994</a>), and one included adults (<a href="./references#CD013437-bbs2-0004" title="NeuIS , PelkaRB . Immunoglobulins in bacterial and viral meningitis. Results of a controlled randomized clinical study of intravenous and intrathecal application. Fortschritte der Medizin1982;100(17):802-9. ">Neu 1982</a>). Both studies only included patients who had not yet received antibiotic treatment. </p> <p>Both studies administered immunoglobulins intrathecally, at doses of either 0.5 mL/kg of 50 mg/mL solution of immunoglobulin M‐enriched immunoglobulins (<a href="./references#CD013437-bbs2-0008" title="SzenbornL , RudowskiZ . Use of immunoglobulin enriched with class IgM antibodies in treatment of purulent meningitis [Zastosowanie immunoglobuliny wzbogaconej w przeciwciała klasy IgM w leczeniu ropnego zapalenia opon mózgowo-rdzeniowych]. Polski Tygodnik lLekarski1994;49(20-2):465-7. ">Szenborn 1994</a>), or 500 mg of immunoglobulins intrathecally (<a href="./references#CD013437-bbs2-0004" title="NeuIS , PelkaRB . Immunoglobulins in bacterial and viral meningitis. Results of a controlled randomized clinical study of intravenous and intrathecal application. Fortschritte der Medizin1982;100(17):802-9. ">Neu 1982</a>). Both studies additionally administered immunoglobulins intravenously at doses of 250 mg/kg, <a href="./references#CD013437-bbs2-0008" title="SzenbornL , RudowskiZ . Use of immunoglobulin enriched with class IgM antibodies in treatment of purulent meningitis [Zastosowanie immunoglobuliny wzbogaconej w przeciwciała klasy IgM w leczeniu ropnego zapalenia opon mózgowo-rdzeniowych]. Polski Tygodnik lLekarski1994;49(20-2):465-7. ">Szenborn 1994</a>, or 10 g, <a href="./references#CD013437-bbs2-0004" title="NeuIS , PelkaRB . Immunoglobulins in bacterial and viral meningitis. Results of a controlled randomized clinical study of intravenous and intrathecal application. Fortschritte der Medizin1982;100(17):802-9. ">Neu 1982</a>, by continuous infusion. Immunoglobulin treatment was administered once every two, <a href="./references#CD013437-bbs2-0004" title="NeuIS , PelkaRB . Immunoglobulins in bacterial and viral meningitis. Results of a controlled randomized clinical study of intravenous and intrathecal application. Fortschritte der Medizin1982;100(17):802-9. ">Neu 1982</a>, or three, <a href="./references#CD013437-bbs2-0008" title="SzenbornL , RudowskiZ . Use of immunoglobulin enriched with class IgM antibodies in treatment of purulent meningitis [Zastosowanie immunoglobuliny wzbogaconej w przeciwciała klasy IgM w leczeniu ropnego zapalenia opon mózgowo-rdzeniowych]. Polski Tygodnik lLekarski1994;49(20-2):465-7. ">Szenborn 1994</a>, days and given for seven to 12 days in total. </p> <p>Only one study reported mortality as an outcome (<a href="./references#CD013437-bbs2-0004" title="NeuIS , PelkaRB . Immunoglobulins in bacterial and viral meningitis. Results of a controlled randomized clinical study of intravenous and intrathecal application. Fortschritte der Medizin1982;100(17):802-9. ">Neu 1982</a>). One study reported neurological symptoms only at end of immunoglobulin treatment, but not at hospital discharge (<a href="./references#CD013437-bbs2-0004" title="NeuIS , PelkaRB . Immunoglobulins in bacterial and viral meningitis. Results of a controlled randomized clinical study of intravenous and intrathecal application. Fortschritte der Medizin1982;100(17):802-9. ">Neu 1982</a>), therefore these data were not included in the review. One study only reported cerebrospinal fluid parameters such as cell counts and protein levels, and no outcomes that were relevant to this review (<a href="./references#CD013437-bbs2-0008" title="SzenbornL , RudowskiZ . Use of immunoglobulin enriched with class IgM antibodies in treatment of purulent meningitis [Zastosowanie immunoglobuliny wzbogaconej w przeciwciała klasy IgM w leczeniu ropnego zapalenia opon mózgowo-rdzeniowych]. Polski Tygodnik lLekarski1994;49(20-2):465-7. ">Szenborn 1994</a>). Neither study reported hearing loss. The authors did not respond to requests for additional data. </p> <p>Neither study was registered in a clinical trial registry prior to study start. Funding sources were not specified in either study. One study appears to have received the study medication from a pharmaceutical company (<a href="./references#CD013437-bbs2-0004" title="NeuIS , PelkaRB . Immunoglobulins in bacterial and viral meningitis. Results of a controlled randomized clinical study of intravenous and intrathecal application. Fortschritte der Medizin1982;100(17):802-9. ">Neu 1982</a>). </p> </section> <section id="CD013437-sec-0049"> <h5 class="title">Heparin</h5> <p>One included study with a total of 15 participants evaluated heparin compared to standard treatment alone (no placebo) (<a href="./references#CD013437-bbs2-0001" title="MacFarlaneJT , ClelandPG , AttaiED , GreenwoodBM . Failure of heparin to alter the outcome of pneumococcal meningitis. BMJ1977;2(6101):1522. ">MacFarlane 1977</a>). The study included adult participants in Nigeria. Timing of antibiotic administration relative to treatment start was not specified. Heparin was administered intravenously at a loading dose of 10,000 units followed by 30,000 units every 24 hours for five days. Outcomes were mortality, days to full consciousness, and development of new focal neurological signs. Total neurological sequelae at hospital discharge and deafness were not reported; the authors responded to our request, but were unable to provide these data. The study was not registered in any clinical trial registry prior to study start. The study was funded by a research foundation. </p> </section> <section id="CD013437-sec-0050"> <h5 class="title">Pentoxifylline</h5> <p>One included study with a total of 57 participants evaluated pentoxifylline compared to standard treatment alone (no placebo) (<a href="./references#CD013437-bbs2-0002" title="Martínez de CuellarC , LoveraD , ArboA . Pentoxifylline as adjunctive therapy in children with acute bacterial meningitis. Revista del Instituto de Medicina Tropical2015;10(2):17-25. ">Martínez de Cuellar 2015</a>). The study included children (3 months to 15 years old) in Paraguay. The study only included patients who had not yet received antibiotic treatment. Pentoxifylline was administered intravenously at a dose of 8 mg/kg/day. The study additionally included a third arm randomised to receive dexamethasone treatment. Outcomes were mortality and neurological sequelae. Reported neurological sequelae included hearing loss using their definition, therefore this information could not be included in the review. The trial authors did not respond to requests for additional data. The study was not registered in any clinical trial registry prior to study start. Funding sources are not specified<i>.</i> </p> </section> <section id="CD013437-sec-0051"> <h5 class="title">Succinic acid, inosine, nicotinamide, and riboflavin mononucleotide mixture</h5> <p>One included study with a total of 30 participants with bacterial meningitis out of a total cohort of 60 participants evaluated a mixture of succinic acid, inosine, nicotinamide, and riboflavin mononucleotide compared to standard treatment alone (no placebo) (<a href="./references#CD013437-bbs2-0007" title="SkripchenkoNV , EgorovaES . Cytoflavin in the complex treatment of neuroinfections in children. Neuroscience and Behavioral Physiology2013;43(2):219-22. SkripchenkoNV , EgorovaES . Cytoflavin in the complex treatment of neuroinfections in children [Primenenie citoflavina v kompleksnoj terapii nejroinfekcij u detej]. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova2011;111(9):28-31. ">Skripchenko 2011</a>). Although many of the components included are dietary supplements or metabolites, two of the components (succinic acid and inosine) may have mechanisms of action against specific receptors (<a href="./references#CD013437-bbs2-0035" title="deCastro FonsecaM , AguiarCJ , da Rocha FrancoJA , GingoldRN , LeiteMF . GPR91: expanding the frontiers of Krebs cycle intermediates. Cell Communication and Signaling2016;14:3.">de Castro Fonseca 2016</a>; <a href="./references#CD013437-bbs2-0039" title="DoyleC , CristofaroV , SullivanMP , AdamRM . Inosine – a multifunctional treatment for complications of neurologic injury. Cellular Physiology and Biochemistry2018;49(6):2293-303.">Doyle 2018</a>), therefore we considered this study to fit our inclusion criteria. The study included children (1 month to 18 years). The study did not specify the country or institution where participants were enrolled, but it presumably took place in Russia. Timing of antibiotic administration relative to treatment start is not specified. The study medication was administered intravenously at a dose of 0.6 mg/kg/day for five days. Outcomes were time to fever resolution, time to resolution of various neurological symptoms, and time to normalisation of cerebrospinal fluid parameters (cell counts and protein levels). Mortality, neurological sequelae on discharge, and hearing loss were not reported, and the authors did not respond to our requests for additional data. The study was not registered in any clinical trial registry prior to study start. Funding sources are not specified. </p> </section> </section> <section id="CD013437-sec-0052"> <h4 class="title">Excluded studies</h4> <p>We excluded 16 studies after full‐text review (see <a href="./references#CD013437-sec-0145" title="">Characteristics of excluded studies</a>). Four studies did not randomise participants and, one was a quasi‐randomised study with inadequate sequence generation. One study tested only antibiotics. One study tested heparin (an eligible intervention) and surgical intervention (ineligible), but only the surgical intervention was randomised. Two studies were editorial comments about other studies and did not present any new data. </p> <p>Six studies tested non‐antibiotic pharmacological compounds whose primary purpose was to affect the degradation or clearance of antibiotics in the body, such as sulbactam, which targets a bacterial enzyme or cilastatin, which targets a human liver enzyme. Our original inclusion criteria did not take into account such a scenario, therefore we clarified our inclusion criteria to exclude pharmacological therapies whose primary function as an adjuvant therapy is to alter pharmacokinetics of antibiotics, and excluded these six studies. </p> </section> </section> <section id="CD013437-sec-0053"> <h3 class="title">Risk of bias in included studies</h3> <p>In many cases inadequate descriptions related to risk of bias were provided, resulting in a judgement of unclear risk of bias. No study was completely free of bias, with at least one judgement of unclear risk for each study. Three studies had a high risk of bias in at least one domain (<a href="#CD013437-fig-0002">Figure 2</a>; <a href="#CD013437-fig-0003">Figure 3</a>). For justification of each judgement, see the risk of bias tables in <a href="./references#CD013437-sec-0144" title="">Characteristics of included studies</a>. </p> <div class="figure" id="CD013437-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph." data-id="CD013437-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph.</p> </div> </div> </div> <div class="figure" id="CD013437-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013437-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013437-sec-0054"> <h4 class="title">Allocation</h4> <p>Sequence generation was adequately described in five studies, by either a random number list or table (<a href="./references#CD013437-bbs2-0002" title="Martínez de CuellarC , LoveraD , ArboA . Pentoxifylline as adjunctive therapy in children with acute bacterial meningitis. Revista del Instituto de Medicina Tropical2015;10(2):17-25. ">Martínez de Cuellar 2015</a>; <a href="./references#CD013437-bbs2-0004" title="NeuIS , PelkaRB . Immunoglobulins in bacterial and viral meningitis. Results of a controlled randomized clinical study of intravenous and intrathecal application. Fortschritte der Medizin1982;100(17):802-9. ">Neu 1982</a>), or computer‐generated block randomisation (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>). Three studies only stated that participants were randomised without describing a randomisation method (<a href="./references#CD013437-bbs2-0001" title="MacFarlaneJT , ClelandPG , AttaiED , GreenwoodBM . Failure of heparin to alter the outcome of pneumococcal meningitis. BMJ1977;2(6101):1522. ">MacFarlane 1977</a>; <a href="./references#CD013437-bbs2-0007" title="SkripchenkoNV , EgorovaES . Cytoflavin in the complex treatment of neuroinfections in children. Neuroscience and Behavioral Physiology2013;43(2):219-22. SkripchenkoNV , EgorovaES . Cytoflavin in the complex treatment of neuroinfections in children [Primenenie citoflavina v kompleksnoj terapii nejroinfekcij u detej]. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova2011;111(9):28-31. ">Skripchenko 2011</a>; <a href="./references#CD013437-bbs2-0008" title="SzenbornL , RudowskiZ . Use of immunoglobulin enriched with class IgM antibodies in treatment of purulent meningitis [Zastosowanie immunoglobuliny wzbogaconej w przeciwciała klasy IgM w leczeniu ropnego zapalenia opon mózgowo-rdzeniowych]. Polski Tygodnik lLekarski1994;49(20-2):465-7. ">Szenborn 1994</a>). Adequate information about allocation concealment (sealed, sequentially numbered envelopes) was only provided in two studies (<a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>); the remaining studies provided no information. </p> </section> <section id="CD013437-sec-0055"> <h4 class="title">Blinding</h4> <p>Blinding was generally poorly documented. Three studies explicitly stated that no blinding of participants or personnel was done (<a href="./references#CD013437-bbs2-0001" title="MacFarlaneJT , ClelandPG , AttaiED , GreenwoodBM . Failure of heparin to alter the outcome of pneumococcal meningitis. BMJ1977;2(6101):1522. ">MacFarlane 1977</a>; <a href="./references#CD013437-bbs2-0002" title="Martínez de CuellarC , LoveraD , ArboA . Pentoxifylline as adjunctive therapy in children with acute bacterial meningitis. Revista del Instituto de Medicina Tropical2015;10(2):17-25. ">Martínez de Cuellar 2015</a>; <a href="./references#CD013437-bbs2-0008" title="SzenbornL , RudowskiZ . Use of immunoglobulin enriched with class IgM antibodies in treatment of purulent meningitis [Zastosowanie immunoglobuliny wzbogaconej w przeciwciała klasy IgM w leczeniu ropnego zapalenia opon mózgowo-rdzeniowych]. Polski Tygodnik lLekarski1994;49(20-2):465-7. ">Szenborn 1994</a>). Two studies did not describe blinding of participants or personnel and did not use a placebo, therefore it is unlikely that blinding was possible (<a href="./references#CD013437-bbs2-0004" title="NeuIS , PelkaRB . Immunoglobulins in bacterial and viral meningitis. Results of a controlled randomized clinical study of intravenous and intrathecal application. Fortschritte der Medizin1982;100(17):802-9. ">Neu 1982</a>; <a href="./references#CD013437-bbs2-0008" title="SzenbornL , RudowskiZ . Use of immunoglobulin enriched with class IgM antibodies in treatment of purulent meningitis [Zastosowanie immunoglobuliny wzbogaconej w przeciwciała klasy IgM w leczeniu ropnego zapalenia opon mózgowo-rdzeniowych]. Polski Tygodnik lLekarski1994;49(20-2):465-7. ">Szenborn 1994</a>). Two studies described in detail the use of opaque syringes and stopcocks to conceal the identity of the intervention, and one study was described as "double blind" and therefore judged to have a low risk of performance bias (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>). </p> <p>None of the included studies mentioned blinding of outcome assessors during neurological or audiological assessments, therefore the risk of detection bias was unclear in all studies. We did not consider vague terms such as 'double blind' an adequate description of blinding of outcome assessors. </p> </section> <section id="CD013437-sec-0056"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed five studies as free from attrition bias, with three studies including intention‐to‐treat analyses (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>), and two studies reporting complete data for all enrolled participants (<a href="./references#CD013437-bbs2-0002" title="Martínez de CuellarC , LoveraD , ArboA . Pentoxifylline as adjunctive therapy in children with acute bacterial meningitis. Revista del Instituto de Medicina Tropical2015;10(2):17-25. ">Martínez de Cuellar 2015</a>; <a href="./references#CD013437-bbs2-0007" title="SkripchenkoNV , EgorovaES . Cytoflavin in the complex treatment of neuroinfections in children. Neuroscience and Behavioral Physiology2013;43(2):219-22. SkripchenkoNV , EgorovaES . Cytoflavin in the complex treatment of neuroinfections in children [Primenenie citoflavina v kompleksnoj terapii nejroinfekcij u detej]. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova2011;111(9):28-31. ">Skripchenko 2011</a>). The remaining studies did not specify the enrolled number of participants compared to the final reported numbers and were thus judged as at unclear risk of attrition bias. </p> </section> <section id="CD013437-sec-0057"> <h4 class="title">Selective reporting</h4> <p>Only three studies had registered a protocol with prespecified outcomes before publication of the study (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>). Of these studies, only two reported all prespecified outcomes or reported protocol changes and were therefore assessed as at low risk of bias (<a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>). None of the other included studies registered prespecified outcomes prior to publication or specified whether reported outcomes were predefined before analysis was carried out; we therefore assessed these studies as having an unclear risk of reporting bias. </p> </section> <section id="CD013437-sec-0058"> <h4 class="title">Other potential sources of bias</h4> <p>In one study (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>), the planned sample size in each group was not achieved, and baseline characteristics of the four groups were not described in sufficient detail to determine whether there were any baseline imbalances. It is unclear what risk of bias these factors add to the study. </p> </section> </section> <section id="CD013437-sec-0059"> <h3 class="title" id="CD013437-sec-0059">Effects of interventions</h3> <p>See: <a href="./full#CD013437-tbl-0001"><b>Summary of findings 1</b> Paracetamol for acute bacterial meningitis</a> </p> <section id="CD013437-sec-0060"> <h4 class="title">Comparison 1: standard treatment plus paracetamol versus standard treatment plus placebo</h4> <p>Three trials (1274 participants who were children) were included in this comparison (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>). See <a href="./full#CD013437-tbl-0001">summary of findings Table 1</a>. Our clinical opinion is that bolus and infusion administration of antibiotics fall within the realm of standard treatment, as they are considered to have clinical equipoise, therefore we combined the identified studies in meta‐analyses regardless of how the antibiotics were administered (bolus or infusion). </p> <section id="CD013437-sec-0061"> <h5 class="title">Primary outcomes</h5> <section id="CD013437-sec-0062"> <h6 class="title">1.1 All‐cause mortality</h6> <p>Three trials (1274 participants) reported this outcome (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>). The pooled data showed that paracetamol may make little or no difference to mortality for children with bacterial meningitis (typical risk ratio (RR) 0.94, 95% confidence interval (CI) 0.81 to 1.09; typical risk difference (RD) −0.02, 95% CI −0.08 to 0.03; I² = 0% for RR and RD; 3 studies, 1274 participants; low certainty evidence; <a href="./references#CD013437-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD013437-sec-0063"> <h6 class="title">1.2 Any hearing loss</h6> <p>Two trials (901 participants) reported this outcome (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>). The pooled data showed that paracetamol may make little or no difference to any hearing loss for children with bacterial meningitis (typical RR 1.04, 95% CI 0.80 to 1.34; typical RD 0.01, 95% CI −0.04 to 0.06; I² = 0% for RR and RD; 2 studies, 901 participants; low certainty evidence; <a href="./references#CD013437-fig-0005" title="">Analysis 1.2</a>). We obtained data from the trial authors. </p> </section> <section id="CD013437-sec-0064"> <h6 class="title">1.3 Any neurological sequelae other than hearing loss</h6> <p>Three trials (1274 participants) reported this outcome (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>). The pooled data showed that paracetamol may make little or no difference to any neurological sequelae other than hearing loss for children with bacterial meningitis (typical RR 1.56, 95% CI 0.98 to 2.50; typical RD 0.08, 95% CI 0.03 to 0.12; I² = 60% for RR and I² = 0% for RD; 3 studies, 1274 participants; low certainty evidence; <a href="./references#CD013437-fig-0006" title="">Analysis 1.3</a>). We obtained data from the authors of two trials (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>). </p> </section> <section id="CD013437-sec-0065"> <h6 class="title">1.4 Adverse events</h6> <p>Three trials (1274 participants) reported no adverse events from treatment in either group (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>). We obtained data from the authors of one trial (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>). See <a href="./references#CD013437-fig-0007" title="">Analysis 1.4</a>. </p> </section> </section> <section id="CD013437-sec-0066"> <h5 class="title">Secondary outcomes</h5> <section id="CD013437-sec-0067"> <h6 class="title">1.5 Severe hearing loss</h6> <p>Two trials (901 participants) reported this outcome (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>). The pooled showed that paracetamol may make little or no difference to severe hearing loss for children with bacterial meningitis (typical RR 0.96, 95% CI 0.67 to 1.36; typical RD −0.01, 95% CI −0.05 to 0.04; I² = 0% for RR and RD; 2 studies, 901 participants; low certainty evidence; <a href="./references#CD013437-fig-0008" title="">Analysis 1.5</a>). We obtained data from the trial authors. </p> </section> <section id="CD013437-sec-0068"> <h6 class="title">1.6 Short‐term neurological sequelae other than hearing loss</h6> <p>Two trials (1096 participants) reported this outcome (<a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>). A higher overall number of participants with short‐term neurological sequelae other than hearing loss was observed in the paracetamol group compared to the placebo group, indicating that paracetamol may lead to slightly more short‐term neurological sequelae other than hearing loss for children with bacterial meningitis (typical RR 1.99, 95% CI 1.40 to 2.81; typical RD 0.08, 95% CI 0.04 to 0.12; I² = 0% for RR and RD; 2 studies, 1096 participants; low certainty evidence; <a href="./references#CD013437-fig-0009" title="">Analysis 1.6</a>). We obtained data from the authors of one trial (<a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>), and we obtained data not published in the trial report for <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a> from results posted to ClinicalTrials.gov. </p> </section> <section id="CD013437-sec-0069"> <h6 class="title">1.7 Long‐term neurological sequelae other than hearing loss</h6> <p>Two trials (901 participants) reported this outcome (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>). A higher overall number of participants with long‐term neurological sequelae other than hearing loss was observed in the paracetamol group compared to the placebo group, indicating that paracetamol may lead to slightly more long‐term neurological sequelae other than hearing loss for children with bacterial meningitis (typical RR 2.32, 95% CI 1.34 to 4.04; typical RD 0.05, 95% CI 0.02 to 0.08; I² = 0% for RR and RD; 2 studies, 901 participants; low certainty evidence; <a href="./references#CD013437-fig-0010" title="">Analysis 1.7</a>). We obtained data from the trial authors. </p> </section> </section> </section> <section id="CD013437-sec-0070"> <h4 class="title">Comparison 2: standard treatment plus immunoglobulins versus standard treatment</h4> <p>Two trials (49 participants who were adults and children) were included in the comparison standard treatment plus immunoglobulins versus standard treatment (no placebo) (<a href="./references#CD013437-bbs2-0004" title="NeuIS , PelkaRB . Immunoglobulins in bacterial and viral meningitis. Results of a controlled randomized clinical study of intravenous and intrathecal application. Fortschritte der Medizin1982;100(17):802-9. ">Neu 1982</a>; <a href="./references#CD013437-bbs2-0008" title="SzenbornL , RudowskiZ . Use of immunoglobulin enriched with class IgM antibodies in treatment of purulent meningitis [Zastosowanie immunoglobuliny wzbogaconej w przeciwciała klasy IgM w leczeniu ropnego zapalenia opon mózgowo-rdzeniowych]. Polski Tygodnik lLekarski1994;49(20-2):465-7. ">Szenborn 1994</a>). See <a href="#CD013437-tbl-0002">Table 1</a>. </p> <div class="table" id="CD013437-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Immunoglobulins for acute bacterial meningitis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with acute bacterial meningitis<br/><b>Settings:</b> hospitals, location unclear<br/><b>Intervention:</b> immunoglobulins<br/><b>Comparison:</b> standard treatment plus immunoglobulins versus standard treatment </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Immunoglobulins</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p><i>during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b><br/>(1 to 515) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.19</b> <br/>(0.01 to 3.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 adults<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any hearing loss</b> </p> <p><i>defined as 40 dB or more not detected by the better ear during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any neurological sequelae other than hearing loss</b> </p> <p><i>defined as health consequences of the infection that involve the central nervous system during the follow‐up period. Can include seizure disorder, focal neurological deficit, ataxia, paresis, or psychomotor retardation</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p><i>during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 adults and children<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe hearing loss</b> </p> <p><i>defined as a threshold of 60 dB or more in the better ear or requiring bilateral hearing aid during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term neurological sequelae other than hearing loss</b> </p> <p><i>defined as sequelae present up to 6 weeks after hospital discharge</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Long‐term neurological sequelae other than hearing loss</b> </p> <p><i>defined as sequelae present between 6 weeks after hospital discharge and the last time point reported in the study</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>dB:</b> decibels; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Limitations in study design: downgraded by two levels due to included study at unclear risk of bias in five domains.<br/><sup>b</sup>Imprecision: downgraded by two levels due to extremely low sample size and few events. </p> </div> </div> <section id="CD013437-sec-0071"> <h5 class="title">Primary outcomes</h5> <section id="CD013437-sec-0072"> <h6 class="title">2.1 All‐cause mortality</h6> <p>One trial (29 participants) reported this outcome (<a href="./references#CD013437-bbs2-0004" title="NeuIS , PelkaRB . Immunoglobulins in bacterial and viral meningitis. Results of a controlled randomized clinical study of intravenous and intrathecal application. Fortschritte der Medizin1982;100(17):802-9. ">Neu 1982</a>). It is uncertain whether immunoglobulins improve mortality for adults or children with bacterial meningitis (typical RR 0.19, 95% CI 0.01 to 3.60; typical RD −0.14, 95% CI −0.35 to 0.06; 1 study; 29 participants; very low certainty evidence; <a href="./references#CD013437-fig-0011" title="">Analysis 2.1</a>). The test for heterogeneity was not applicable to this outcome. </p> </section> <section id="CD013437-sec-0073"> <h6 class="title">2.2 Any hearing loss</h6> <p>Not reported.</p> </section> <section id="CD013437-sec-0074"> <h6 class="title">2.3 Any neurological sequelae other than hearing loss</h6> <p>Not reported.</p> </section> <section id="CD013437-sec-0075"> <h6 class="title">2.4 Adverse events</h6> <p>Two trials (49 participants who were adults and children) reported this outcome (<a href="./references#CD013437-bbs2-0004" title="NeuIS , PelkaRB . Immunoglobulins in bacterial and viral meningitis. Results of a controlled randomized clinical study of intravenous and intrathecal application. Fortschritte der Medizin1982;100(17):802-9. ">Neu 1982</a>; <a href="./references#CD013437-bbs2-0008" title="SzenbornL , RudowskiZ . Use of immunoglobulin enriched with class IgM antibodies in treatment of purulent meningitis [Zastosowanie immunoglobuliny wzbogaconej w przeciwciała klasy IgM w leczeniu ropnego zapalenia opon mózgowo-rdzeniowych]. Polski Tygodnik lLekarski1994;49(20-2):465-7. ">Szenborn 1994</a>). No adverse events from treatment were observed. See <a href="./references#CD013437-fig-0012" title="">Analysis 2.2</a>. </p> </section> </section> <section id="CD013437-sec-0076"> <h5 class="title">Secondary outcomes</h5> <section id="CD013437-sec-0077"> <h6 class="title">2.5 Severe hearing loss</h6> <p>Not reported.</p> </section> <section id="CD013437-sec-0078"> <h6 class="title">2.6 Short‐term neurological sequelae other than hearing loss</h6> <p>Not reported.</p> </section> <section id="CD013437-sec-0079"> <h6 class="title">2.7 Long‐term neurological sequelae other than hearing loss</h6> <p>Not reported.</p> </section> </section> </section> <section id="CD013437-sec-0080"> <h4 class="title">Comparison 3: standard treatment plus heparin versus standard treatment</h4> <p>We could not perform any meta‐analysis for this comparison because we identified only one trial (15 participants who were adults) for inclusion (<a href="./references#CD013437-bbs2-0001" title="MacFarlaneJT , ClelandPG , AttaiED , GreenwoodBM . Failure of heparin to alter the outcome of pneumococcal meningitis. BMJ1977;2(6101):1522. ">MacFarlane 1977</a>). See <a href="#CD013437-tbl-0003">Table 2</a>. </p> <div class="table" id="CD013437-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Heparin for acute bacterial meningitis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with acute bacterial meningitis<br/><b>Settings:</b> hospital in Nigeria<br/><b>Intervention:</b> heparin<br/><b>Comparison:</b> standard treatment plus heparin versus standard treatment </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Immunoglobulins</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p><i>during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>572 per 1000</b><br/>(147 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.29</b> <br/>(0.59 to 8.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 adults<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any hearing loss</b> </p> <p><i>defined as 40 dB or more not detected by the better ear during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any neurological sequelae other than hearing loss</b> </p> <p><i>defined as health consequences of the infection that involve the central nervous system during the follow‐up period. Can include seizure disorder, focal neurological deficit, ataxia, paresis, or psychomotor retardation</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p><i>during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe hearing loss</b> </p> <p><i>defined as a threshold of 60 dB or more in the better ear or requiring bilateral hearing aid during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term neurological sequelae other than hearing loss</b> </p> <p><i>defined as sequelae present up to 6 weeks after hospital discharge</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Long‐term neurological sequelae other than hearing loss</b> </p> <p><i>defined as sequelae present between 6 weeks after hospital discharge and the last time point reported in the study</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>dB:</b> decibels; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Limitations in study design: downgraded by two levels due to included study at high or unclear risk of bias in four domains.<br/><sup>b</sup>Imprecision: downgraded by two levels due to extremely low sample size and few events. </p> </div> </div> <section id="CD013437-sec-0081"> <h5 class="title">Primary outcomes</h5> <section id="CD013437-sec-0082"> <h6 class="title">3.1 All‐cause mortality</h6> <p>One trial (15 participants) reported this outcome (<a href="./references#CD013437-bbs2-0001" title="MacFarlaneJT , ClelandPG , AttaiED , GreenwoodBM . Failure of heparin to alter the outcome of pneumococcal meningitis. BMJ1977;2(6101):1522. ">MacFarlane 1977</a>). It is uncertain whether heparin improves mortality for adults with bacterial meningitis (typical RR 2.29, 95% CI 0.59 to 8.91; typical RD 0.32, 95% CI −0.15 to 0.80; 1 study, 15 participants; very low certainty evidence; <a href="./references#CD013437-fig-0013" title="">Analysis 3.1</a>). The test for heterogeneity was not applicable to this outcome. </p> </section> <section id="CD013437-sec-0083"> <h6 class="title">3.2 Any hearing loss</h6> <p>Not reported.</p> </section> <section id="CD013437-sec-0084"> <h6 class="title">3.3 Any neurological sequelae other than hearing loss</h6> <p>Not reported.</p> </section> <section id="CD013437-sec-0085"> <h6 class="title">3.4 Adverse events</h6> <p>Not reported.</p> </section> </section> <section id="CD013437-sec-0086"> <h5 class="title">Secondary outcomes</h5> <section id="CD013437-sec-0087"> <h6 class="title">3.5 Severe hearing loss</h6> <p>Not reported.</p> </section> <section id="CD013437-sec-0088"> <h6 class="title">3.6 Short‐term neurological sequelae other than hearing loss</h6> <p>Not reported.</p> </section> <section id="CD013437-sec-0089"> <h6 class="title">3.7 Long‐term neurological sequelae other than hearing loss</h6> <p>Not reported.</p> </section> </section> </section> <section id="CD013437-sec-0090"> <h4 class="title">Comparison 4: standard treatment plus pentoxifylline versus standard treatment</h4> <p>We could not perform any meta‐analysis for this comparison because we identified only one trial (57 participants who were children) for inclusion (<a href="./references#CD013437-bbs2-0002" title="Martínez de CuellarC , LoveraD , ArboA . Pentoxifylline as adjunctive therapy in children with acute bacterial meningitis. Revista del Instituto de Medicina Tropical2015;10(2):17-25. ">Martínez de Cuellar 2015</a>). See <a href="#CD013437-tbl-0004">Table 3</a>. </p> <div class="table" id="CD013437-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Pentoxifylline for acute bacterial meningitis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> children with acute bacterial meningitis<br/><b>Settings:</b> hospital in Paraguay<br/><b>Intervention:</b> pentoxifylline<br/><b>Comparison:</b> standard treatment plus pentoxifylline versus standard treatment </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Immunoglobulins</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p><i>during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>115 per 1000</b><br/>(23 to 573) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> <br/>(0.25 to 6.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 children<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any hearing loss</b> </p> <p><i>defined as 40 dB or more not detected by the better ear during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any neurological sequelae other than hearing loss</b> </p> <p><i>defined as health consequences of the infection that involve the central nervous system during the follow‐up period. Can include seizure disorder, focal neurological deficit, ataxia, paresis, or psychomotor retardation</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p><i>during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe hearing loss</b> </p> <p><i>defined as a threshold of 60 dB or more in the better ear or requiring bilateral hearing aid during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term neurological sequelae other than hearing loss</b> </p> <p><i>defined as sequelae present up to 6 weeks after hospital discharge</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Long‐term neurological sequelae other than hearing loss</b> </p> <p><i>defined as sequelae present between 6 weeks after hospital discharge and the last time point reported in the study</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>dB:</b> decibels; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Limitations in study design: downgraded by two levels due to included study at high or unclear risk of bias in four domains.<br/><sup>b</sup>Imprecision: downgraded by two levels due to extremely low sample size and few events. </p> </div> </div> <section id="CD013437-sec-0091"> <h5 class="title">Primary outcomes</h5> <section id="CD013437-sec-0092"> <h6 class="title">4.1 All‐cause mortality</h6> <p>One trial (57 participants) reported this outcome (<a href="./references#CD013437-bbs2-0002" title="Martínez de CuellarC , LoveraD , ArboA . Pentoxifylline as adjunctive therapy in children with acute bacterial meningitis. Revista del Instituto de Medicina Tropical2015;10(2):17-25. ">Martínez de Cuellar 2015</a>). It is uncertain whether pentoxifylline improves mortality for children with bacterial meningitis (typical RR 1.26, 95% CI 0.25 to 6.30; typical RD 0.02, 95% CI −0.14 to 0.18; 1 study, 57 participants; very low certainty evidence; <a href="./references#CD013437-fig-0014" title="">Analysis 4.1</a>). The test for heterogeneity was not applicable. </p> </section> <section id="CD013437-sec-0093"> <h6 class="title">4.2 Any hearing loss</h6> <p>Not reported.</p> </section> <section id="CD013437-sec-0094"> <h6 class="title">4.3 Any neurological sequelae other than hearing loss</h6> <p>Not reported.</p> </section> <section id="CD013437-sec-0095"> <h6 class="title">4.4 Adverse events</h6> <p>Not reported.</p> </section> </section> <section id="CD013437-sec-0096"> <h5 class="title">Secondary outcomes</h5> <section id="CD013437-sec-0097"> <h6 class="title">4.5 Severe hearing loss</h6> <p>Not reported.</p> </section> <section id="CD013437-sec-0098"> <h6 class="title">4.6 Short‐term neurological sequelae other than hearing loss</h6> <p>Not reported.</p> </section> <section id="CD013437-sec-0099"> <h6 class="title">4.7 Long‐term neurological sequelae other than hearing loss</h6> <p>Not reported.</p> </section> </section> </section> <section id="CD013437-sec-0100"> <h4 class="title">Comparison 5: standard treatment plus succinic acid, inosine, nicotinamide, and riboflavin mononucleotide mixture versus standard treatment </h4> <p>We could not perform any meta‐analysis for this comparison because we identified only one trial for inclusion (<a href="./references#CD013437-bbs2-0007" title="SkripchenkoNV , EgorovaES . Cytoflavin in the complex treatment of neuroinfections in children. Neuroscience and Behavioral Physiology2013;43(2):219-22. SkripchenkoNV , EgorovaES . Cytoflavin in the complex treatment of neuroinfections in children [Primenenie citoflavina v kompleksnoj terapii nejroinfekcij u detej]. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova2011;111(9):28-31. ">Skripchenko 2011</a>). </p> <section id="CD013437-sec-0101"> <h5 class="title">Primary outcomes</h5> <section id="CD013437-sec-0102"> <h6 class="title">5.1 All‐cause mortality</h6> <p>Not reported.</p> </section> <section id="CD013437-sec-0103"> <h6 class="title">5.2 Any hearing loss</h6> <p>Not reported.</p> </section> <section id="CD013437-sec-0104"> <h6 class="title">5.3 Any neurological sequelae other than hearing loss</h6> <p>Not reported.</p> </section> <section id="CD013437-sec-0105"> <h6 class="title">5.4 Adverse events</h6> <p><a href="./references#CD013437-bbs2-0007" title="SkripchenkoNV , EgorovaES . Cytoflavin in the complex treatment of neuroinfections in children. Neuroscience and Behavioral Physiology2013;43(2):219-22. SkripchenkoNV , EgorovaES . Cytoflavin in the complex treatment of neuroinfections in children [Primenenie citoflavina v kompleksnoj terapii nejroinfekcij u detej]. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova2011;111(9):28-31. ">Skripchenko 2011</a> reported a 3.3% rate of allergic reactions in the whole study population (60 participants: 30 with bacterial meningitis and 30 with viral encephalitis). </p> </section> </section> <section id="CD013437-sec-0106"> <h5 class="title">Secondary outcomes</h5> <section id="CD013437-sec-0107"> <h6 class="title">5.5 Severe hearing loss</h6> <p>Not reported.</p> </section> <section id="CD013437-sec-0108"> <h6 class="title">5.6 Short‐term neurological sequelae other than hearing loss</h6> <p>Not reported.</p> </section> <section id="CD013437-sec-0109"> <h6 class="title">5.7 Long‐term neurological sequelae other than hearing loss</h6> <p>Not reported.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013437-sec-0110" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013437-sec-0110"></div> <section id="CD013437-sec-0111"> <h3 class="title" id="CD013437-sec-0111">Summary of main results</h3> <p>We included eight trials evaluating non‐corticosteroid pharmacological adjuvant therapies in bacterial meningitis. We included randomised controlled trials only, which are the highest form of evidence available. Our search strategy followed the criteria and standard methods of Cochrane. In order to minimise reporting bias and capture all of the available evidence, we did not exclude studies based on language or publication status. We included three studies of paracetamol (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>), two studies of immunoglobulins (<a href="./references#CD013437-bbs2-0004" title="NeuIS , PelkaRB . Immunoglobulins in bacterial and viral meningitis. Results of a controlled randomized clinical study of intravenous and intrathecal application. Fortschritte der Medizin1982;100(17):802-9. ">Neu 1982</a>; <a href="./references#CD013437-bbs2-0008" title="SzenbornL , RudowskiZ . Use of immunoglobulin enriched with class IgM antibodies in treatment of purulent meningitis [Zastosowanie immunoglobuliny wzbogaconej w przeciwciała klasy IgM w leczeniu ropnego zapalenia opon mózgowo-rdzeniowych]. Polski Tygodnik lLekarski1994;49(20-2):465-7. ">Szenborn 1994</a>), one study of heparin (<a href="./references#CD013437-bbs2-0001" title="MacFarlaneJT , ClelandPG , AttaiED , GreenwoodBM . Failure of heparin to alter the outcome of pneumococcal meningitis. BMJ1977;2(6101):1522. ">MacFarlane 1977</a>), one study of pentoxifylline (<a href="./references#CD013437-bbs2-0002" title="Martínez de CuellarC , LoveraD , ArboA . Pentoxifylline as adjunctive therapy in children with acute bacterial meningitis. Revista del Instituto de Medicina Tropical2015;10(2):17-25. ">Martínez de Cuellar 2015</a>), and one study of a mixture of succinic acid, inosine, nicotinamide, and riboflavin mononucleotide (<a href="./references#CD013437-bbs2-0007" title="SkripchenkoNV , EgorovaES . Cytoflavin in the complex treatment of neuroinfections in children. Neuroscience and Behavioral Physiology2013;43(2):219-22. SkripchenkoNV , EgorovaES . Cytoflavin in the complex treatment of neuroinfections in children [Primenenie citoflavina v kompleksnoj terapii nejroinfekcij u detej]. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova2011;111(9):28-31. ">Skripchenko 2011</a>). We also identified one study listed as ongoing at ClinicalTrials.gov that will evaluate phenytoin (<a href="./references#CD013437-bbs2-0025" title="NCT01478035. Study on the efficacy of phenytoin in the prophylaxis of seizures of patients with pneumococcal meningitis at least 50 yrs old [Study on the efficacy of phenytoin in the prophylaxis of seizures of patients with pneumococcal meningitis at least 50 yrs old. A multi-center comparative randomized double-blind and placebo-controlled clinical trial]. clinicaltrials.gov/ct2/show/NCT01478035 (first received 23 November 2011). ">NCT01478035</a>). Overall, most of the included studies had small numbers of participants, which is likely attributed to the nature of the disease, which has relatively low incidence rates in many of the included countries, and tends to result in early mortality and morbidity, creating difficulties in participant recruitment even in high‐incidence areas. We clarified our inclusion criteria to state that pharmacological therapies that primarily alter pharmacokinetics of antibiotics (such as cilastatin or sulbactam) should be excluded. We did not include corticosteroids, as this intervention has already been reviewed (<a href="./references#CD013437-bbs2-0034" title="BrouwerMC , McIntyreP , PrasadK , vande BeekD . Corticosteroids for acute bacterial meningitis. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD004405. [DOI: 10.1002/14651858.CD004405.pub5]">Brouwer 2015</a>). We also did not include non‐pharmacological therapies, which would have led to an overly broad review topic, and because the main non‐pharmacological therapy (osmotic therapies) has been reviewed previously (<a href="./references#CD013437-bbs2-0071" title="WallEC , AjdukiewiczKM , BergmanH , HeydermanRS , GarnerP . Osmotic therapies added to antibiotics for acute bacterial meningitis. Cochrane Database of Systematic Reviews2018, Issue 2. Art. No: CD008806. [DOI: 10.1002/14651858.CD008806.pub2]">Wall 2018</a>). </p> <p>Given that the therapies that have been subjected to similar reviews are distinct from the therapies included in this review, we do not believe that they confound the results of this review. One exception may be the Cochrane Review on corticosteroids in bacterial meningitis first published in 2010 (<a href="./references#CD013437-bbs2-0033" title="BrouwerMC , McIntyreP , deGansJ , PrasadK , vande BeekD . Corticosteroids for acute bacterial meningitis. Cochrane Database of Systematic Reviews2010, Issue 9. Art. No: CD004405. [DOI: 10.1002/14651858.CD004405.pub3]">Brouwer 2010b</a>), which arguably led to a change in clinical practice, with corticosteroids being administered routinely as an adjunctive treatment. Consequently, there could be some confounding when combining studies that recruited the majority participants before corticosteroids became routinely recommended (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>), and those recruiting participants after this time (<a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>). This also highlights the fact that the definition of 'standard treatment' is a moving target due to changing practice as more evidence is obtained, and is further confounded by potential regional differences in practice. </p> <p>We found that paracetamol may make little or no difference to mortality (low certainty evidence) and may make little or no difference to any hearing loss, severe hearing loss, and any neurological sequelae other than hearing loss (low certainty evidence). All studies reported zero adverse events that were attributed to the intervention. Paracetamol may lead to slightly more short‐ and long‐term neurological sequelae compared to standard treatment alone (low certainty evidence), although it had no effect on pooled neurological sequelae. This can be explained by the significant heterogeneity in the outcome any neurological sequelae. Although the three paracetamol studies had some methodological heterogeneity in terms of administration of antibiotics and duration of treatment, we believe that they were similar enough to warrant combination in a meta‐analysis. We rated the certainty of evidence as low (GRADE) for mortality (limitations in study design of most of the included trials, and high level of uncertainty in the absolute effects), and low (GRADE) for any hearing loss, any neurological sequelae other than hearing loss, adverse events, severe hearing loss, and short‐ and long‐term neurological sequelae (limitations in study design and imprecision of estimates). </p> <p>Reduction of fever is thought to be an advantage in patients with fever and cerebral irritability in a population prone to seizures, such as those with bacterial meningitis. Due to the low certainty of the evidence, we do not believe that much emphasis should be placed on the slightly larger number of short‐ and long‐term neurological sequelae in the paracetamol‐treated group; however, the benefits of fever have been highlighted previously. Antipyretic drugs including paracetamol were associated with an increased duration and severity of symptoms in some viral infections (<a href="./references#CD013437-bbs2-0038" title="DoranTF , De AngelisC , BaumgardnerRA , MellitsED . Acetaminophen: more harm than good for chickenpox?Journal of Pediatrics1989;114(6):1045-8.">Doran 1989</a>; <a href="./references#CD013437-bbs2-0042" title="GrahamNM , BurrellCJ , DouglasRM , DebelleP , DaviesL . Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. Journal of Infectious Diseases1990;162(6):1277-82.">Graham 1990</a>). Observational studies indicate that elevated temperatures are associated with improved outcomes in patients hospitalised with bacterial and fungal infections (<a href="./references#CD013437-bbs2-0026" title="AhkeeS , SrinathL , RamirezJ . Community-acquired pneumonia in the elderly: association of mortality with lack of fever and leukocytosis. Southern Medical Journal1997;90(3):296-8.">Ahkee 1997</a>; <a href="./references#CD013437-bbs2-0047" title="LeeBH , InuiD , SuhGY , KimJY , KwonJY , ParkJ , et al. Fever and antipyretic in critically ill patients evaluation (FACE) study group. Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis: multi-centered prospective observational study. Critical Care2012;16(1):R33.">Lee 2012</a>; <a href="./references#CD013437-bbs2-0049" title="LeroyO , GangneuxJP , MontraversP , MiraJP , GouinF , SolletJP , et al, AmarCand Study Group. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Critical Care Medicine2009;37(5):1612-8.">Leroy 2009</a>; <a href="./references#CD013437-bbs2-0062" title="SaxenaM , YoungP , PilcherD , BaileyM , HarrisonD , BellomoR , et al. Early temperature and mortality in critically ill patients with acute neurological diseases: trauma and stroke differ from infection. Intensive Care Medicine2015;41(5):823-32.">Saxena 2015</a>; <a href="./references#CD013437-bbs2-0072" title="YoungPJ , SaxenaM , BeasleyR , BellomoR , BaileyM , PilcherD , et al. Early peak temperature and mortality in critically ill patients with or without infection. Intensive Care Medicine2012;38:437-44.">Young 2012</a>), and this effect is lost at temperatures higher than 40 °C. On the other extreme, induced hypothermia did not improve outcomes and may even be harmful in bacterial meningitis (<a href="./references#CD013437-bbs2-0054" title="MourvillierB , TubachF , vande BeekD , GarotD , PichonN , GeorgesH , et al. Induced hypothermia in severe bacterial meningitis: a randomized clinical trial. JAMA2013;310(20):2174-83.">Mourvillier 2013</a>). Despite its widespread use, the mechanism of action of paracetamol is not fully elucidated (<a href="./references#CD013437-bbs2-0060" title="PrzybyłaGW , SzychowskiKA , GmińskiJ . Paracetamol - an old drug with new mechanisms of action. Clinical and Experimental Pharmacology and Physiology2020;48(1):3-19.">Przybyła 2020</a>), therefore it is unclear why it might affect neurological sequelae but not mortality, and whether any effects are due to the antipyretic effects of paracetamol or another off‐target effect. </p> <p>In the included studies, paracetamol was used regardless of the presence of fever, and the generalisation of our results to a setting in which paracetamol is used only in patients with a high fever is uncertain. This is further supported by the fact that the duration of fever did not differ between paracetamol and placebo groups in the two studies that reported this (<a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>). In <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>, a significantly higher number of participants received ibuprofen in the first four days in the placebo group than in the paracetamol group, indicating a higher need for antipyretic treatment in that group, whilst there was no difference in ibuprofen use between paracetamol and placebo groups in <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>. The use of other antipyretics could confound the results, particularly as the three paracetamol studies were carried out in a setting where patients frequently present to the hospital late in the disease course, and fever may have been treated with different agents prior to enrolment. Patients in these settings are also frequently severely ill, may vary greatly in their general condition upon arrival, and have many comorbidities such as undernourishment and infection with HIV or malaria, which further limits the generalisability of these results. </p> <p>Of the two studies evaluating immunoglobulins, only one reported mortality. It is uncertain whether immunoglobulins improve mortality because the certainty of the evidence is very low. Both studies reported zero adverse events that were attributed to the intervention (very low certainty evidence). None of our other prespecified outcomes were reported. We rated the certainty of evidence as very low (GRADE). </p> <p>One study evaluated heparin. It is uncertain whether heparin improves mortality because the certainty of the evidence is very low. None of our other prespecified outcomes were reported. We rated the certainty of evidence as very low (GRADE). </p> <p>One study evaluated pentoxifylline. It is uncertain whether pentoxifylline improves mortality because the certainty of the evidence is very low. The study reported zero adverse events that were attributed to the intervention. None of our other prespecified outcomes were reported. We rated the certainty of evidence as very low (GRADE). </p> <p>In the one study evaluating a mixture of succinic acid, inosine, nicotinamide, and riboflavin mononucleotide, the only adverse events reported were allergic reactions, at a rate of 3.33% in the intervention group. None of our other prespecified outcomes were reported. We rated the certainty of evidence as very low (GRADE). </p> </section> <section id="CD013437-sec-0112"> <h3 class="title" id="CD013437-sec-0112">Overall completeness and applicability of evidence</h3> <p>Although only three studies evaluated paracetamol, it is unclear whether further studies would change the conclusions of this analysis. The paracetamol studies used different antibiotic treatments and different lengths of paracetamol treatment; however, we judged them to be sufficiently similar to group together for the purposes of our analysis. <a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a> did not record short‐term neurological sequelae, whilst <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a> reported sequelae only upon hospital discharge. <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a> provided unpublished data on both short‐ and long‐term neurological sequelae. The participants in these studies were children, and so the applicability of the findings to adult bacterial meningitis is unclear. Paracetamol was used in the included studies regardless of the presence of fever, and the generalisation of our results to a setting in which paracetamol is used only in patients with a high fever is uncertain. All of the other interventions identified in this review were tested in only one or two included studies, and all in small numbers of participants. Consequently, there is insufficient evidence to support or reject the use of paracetamol, immunoglobulins, heparin, pentoxifylline, or succinic acid, inosine, nicotinamide, and riboflavin mononucleotide mixture as an adjuvant therapy in the treatment of people with acute bacterial meningitis. </p> </section> <section id="CD013437-sec-0113"> <h3 class="title" id="CD013437-sec-0113">Quality of the evidence</h3> <p>We assessed the certainty of the evidence using the GRADE approach (<a href="./references#CD013437-bbs2-0041" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 11 March 2019. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). All of the studies evaluating paracetamol had an unclear risk of bias in at least one domain, resulting in the certainty of the evidence being downgraded for all outcomes (<a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>; <a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>). All outcomes except for mortality had either few events or significant heterogeneity in the effect estimates, resulting in downgrading of the certainty of the evidence an additional level for all outcomes other than mortality. The certainty of evidence was thus moderate for mortality and low for all other outcomes in the analyses of paracetamol (<a href="./full#CD013437-tbl-0001">summary of findings Table 1</a>). </p> <p>The certainty of evidence was very low for all reported outcomes in the analyses of immunoglobulins, heparin, and pentoxifylline, due to very small sample sizes and an unclear or high risk of bias in most domains. </p> </section> <section id="CD013437-sec-0114"> <h3 class="title" id="CD013437-sec-0114">Potential biases in the review process</h3> <p>We used standard Cochrane methods in order to minimise any bias in the review process. The major limitation of this review is the fact that most of the identified interventions were tested in only a small number of studies with few participants, and many of the studies had high or unclear risk of bias in most domains, leading to low or very low certainty evidence for most outcomes. Lack of response to our contact with study authors also limited the available data for most outcomes in this review. Some of the data included in this review were obtained from correspondence with study authors or from results posted to ClinicalTrials.gov, therefore some of the conclusions of the review are based on non‐peer reviewed data. </p> </section> <section id="CD013437-sec-0115"> <h3 class="title" id="CD013437-sec-0115">Agreements and disagreements with other studies or reviews</h3> <p>We are not aware of any other systematic reviews examining non‐corticosteroid pharmacological therapies in bacterial meningitis. In one guideline for the diagnosis and treatment of bacterial meningitis (<a href="./references#CD013437-bbs2-0066" title="vande BeekD , CabellosC , DzupovaO , EspositoS , KleinM , KloekAT , et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clinical Microbiology and Infection2016;22(Suppl 3):37-62.">van de Beek 2016b</a>), there is a section about other adjuvant therapies in bacterial meningitis, for which a systematic literature search was performed. In this guideline some of the studies included in this review were identified, including two of the paracetamol studies, <a href="./references#CD013437-bbs2-0003" title="MolyneuxEM , KawazaK , PhiriA , ChimalizeniY , MankhamboL , SchwalbeE , et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatric Infectious Disease Journal2014;33(2):214-6. NCT00619203. Oral glycerol and high-dose rectal paracetamol to improve the prognosis of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/NCT00619203 (first received 20 February 2008). ">Molyneux 2014</a>; <a href="./references#CD013437-bbs2-0005" title="ISRCTN62824827. Slow initial beta-lactam infusion, and high-dose paracetamol to improve the prognosis of childhood bacterial meningitis, especially of pneumococcal meningitis. www.isrctn.com/ISRCTN62824827 (first received 22 August 2005). PelkonenT , RoineI , CruzeiroML , PitkärantaA , KatajaM , PeltolaH . Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infectious Diseases2011;11(8):613-21. ">Pelkonen 2011</a>, and the heparin study (<a href="./references#CD013437-bbs2-0001" title="MacFarlaneJT , ClelandPG , AttaiED , GreenwoodBM . Failure of heparin to alter the outcome of pneumococcal meningitis. BMJ1977;2(6101):1522. ">MacFarlane 1977</a>). They additionally identified a non‐randomised study of immunoglobulins (<a href="./references#CD013437-bbs2-0018" title="NoackR , SzugsC , ScholzH . Immunoglobulins in the treatment of bacterial meningitis in childhood [Immunglobuline bei der Behandlung der bakteriellen Meningitisim Kindesalter]. Infection1987;15(1):11-5. ">Noack 1987</a>), and a post hoc subgroup analysis of bacterial meningitis patients included in randomised controlled trials that examine activated protein C (<a href="./references#CD013437-bbs2-0069" title="VincentJL , NadelS , KutsogiannisDJ , GibneyRT , YanSB , WyssVL , et al. Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies. Critical Care2005;9:Article number R331.">Vincent 2005</a>), neither of which fulfilled the inclusion criteria of this review. The authors of <a href="./references#CD013437-bbs2-0066" title="vande BeekD , CabellosC , DzupovaO , EspositoS , KleinM , KloekAT , et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clinical Microbiology and Infection2016;22(Suppl 3):37-62.">van de Beek 2016b</a> concluded that heparin is not recommended due to higher mortality in the heparin‐treated group, and that paracetamol does not improve outcome, although they did not describe the specific outcomes evaluated. Our conclusions regarding these two treatments are largely the same, except with the addition of one more paracetamol study that has been published since (<a href="./references#CD013437-bbs2-0006" title="NCT01540838. Slow initial β-lactam infusion with high-dose paracetamol to improve the outcomes of childhood bacterial meningitis. clinicaltrials.gov/ct2/show/nct01540838 (first received 24 September 2019). SavoniusO , RugemaliraE , RoineI , CruzeiroML , PeltolaH , PelkonenT . Extended continuous β-lactam infusion with oral acetaminophen in childhood bacterial meningitis: a randomized, double-blind clinical trial. Clinical Infectious Diseases2020;72(10):1738-44. [DOI: 10.1093/cid/ciaa341]">Savonius 2020</a>). In our analysis, low‐certainty evidence indicates that paracetamol may lead to slightly more short‐ and long‐term neurological sequelae other than hearing loss. The guideline did not identify any of the other studies included in our review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013437-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/urn:x-wiley:14651858:media:CD013437:CD013437-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD013437-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_t/tCD013437-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/full#CD013437-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013437-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/urn:x-wiley:14651858:media:CD013437:CD013437-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph." data-id="CD013437-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_t/tCD013437-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/full#CD013437-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013437-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/urn:x-wiley:14651858:media:CD013437:CD013437-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013437-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_t/tCD013437-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/full#CD013437-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013437-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/urn:x-wiley:14651858:media:CD013437:CD013437-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol for acute bacterial meningitis, Outcome 1: Mortality" data-id="CD013437-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_t/tCD013437-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol for acute bacterial meningitis, Outcome 1: Mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/references#CD013437-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013437-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/urn:x-wiley:14651858:media:CD013437:CD013437-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol for acute bacterial meningitis, Outcome 2: Any hearing loss" data-id="CD013437-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_t/tCD013437-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol for acute bacterial meningitis, Outcome 2: Any hearing loss</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/references#CD013437-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013437-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/urn:x-wiley:14651858:media:CD013437:CD013437-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol for acute bacterial meningitis, Outcome 3: Any neurological sequelae other than hearing loss" data-id="CD013437-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_t/tCD013437-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol for acute bacterial meningitis, Outcome 3: Any neurological sequelae other than hearing loss </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/references#CD013437-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013437-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/urn:x-wiley:14651858:media:CD013437:CD013437-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol for acute bacterial meningitis, Outcome 4: Adverse events" data-id="CD013437-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_t/tCD013437-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol for acute bacterial meningitis, Outcome 4: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/references#CD013437-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013437-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/urn:x-wiley:14651858:media:CD013437:CD013437-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol for acute bacterial meningitis, Outcome 5: Severe hearing loss" data-id="CD013437-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_t/tCD013437-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol for acute bacterial meningitis, Outcome 5: Severe hearing loss </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/references#CD013437-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013437-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/urn:x-wiley:14651858:media:CD013437:CD013437-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol for acute bacterial meningitis, Outcome 6: Short‐term neurologic sequelae" data-id="CD013437-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_t/tCD013437-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol for acute bacterial meningitis, Outcome 6: Short‐term neurologic sequelae </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/references#CD013437-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013437-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/urn:x-wiley:14651858:media:CD013437:CD013437-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol for acute bacterial meningitis, Outcome 7: Long‐term neurological sequelae" data-id="CD013437-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_t/tCD013437-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol for acute bacterial meningitis, Outcome 7: Long‐term neurological sequelae </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/references#CD013437-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013437-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/urn:x-wiley:14651858:media:CD013437:CD013437-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Immunoglobulins for acute bacterial meningitis, Outcome 1: Mortality" data-id="CD013437-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_t/tCD013437-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Immunoglobulins for acute bacterial meningitis, Outcome 1: Mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/references#CD013437-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013437-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/urn:x-wiley:14651858:media:CD013437:CD013437-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Immunoglobulins for acute bacterial meningitis, Outcome 2: Adverse events" data-id="CD013437-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_t/tCD013437-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Immunoglobulins for acute bacterial meningitis, Outcome 2: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/references#CD013437-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013437-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/urn:x-wiley:14651858:media:CD013437:CD013437-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Heparin for acute bacterial meningitis, Outcome 1: Mortality" data-id="CD013437-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_t/tCD013437-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Heparin for acute bacterial meningitis, Outcome 1: Mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/references#CD013437-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013437-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/urn:x-wiley:14651858:media:CD013437:CD013437-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pentoxifylline for acute bacterial meningitis, Outcome 1: Mortality" data-id="CD013437-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_t/tCD013437-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Pentoxifylline for acute bacterial meningitis, Outcome 1: Mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/references#CD013437-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/media/CDSR/CD013437/image_n/nCD013437-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013437-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Paracetamol for acute bacterial meningitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Paracetamol for acute bacterial meningitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with acute bacterial meningitis<br/><b>Settings:</b> hospitals in Malawi and Angola<br/><b>Intervention:</b> paracetamol<br/><b>Comparison:</b> standard treatment plus paracetamol versus standard treatment plus placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Paracetamol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p><i>during the follow‐up period</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>374 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>352 per 1000</b><br/>(303 to 408) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/>(0.81 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1274 children<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any hearing loss</b> </p> <p><i>defined as 40 dB or more not detected by the better ear during the follow‐up period</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>188 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>196 per 1000</b><br/>(150 to 252) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> <br/>(0.8 to 1.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>901 children<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any neurological sequelae other than hearing loss</b> </p> <p><i>defined as health consequences of the infection that involve the central nervous system during the follow‐up period. Can include seizure disorder, focal neurological deficit, ataxia, paresis, or psychomotor retardation</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>206 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>321 per 1000</b><br/>(202 to 515) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.56</b> <br/>(0.98 to 2.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1274 children<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p><i>during the follow‐up period</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1274 children<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe hearing loss</b> </p> <p><i>defined as a threshold of 60 dB or more in the better ear or requiring bilateral hearing aid during the follow‐up period</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>122 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>117 per 1000</b><br/>(82 to 166) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> <br/>(0.67 to 1.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>901 children<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term neurological sequelae other than hearing loss</b> </p> <p><i>defined as sequelae present up to 6 weeks after hospital discharge</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>79 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>157 per 1000</b><br/>(111 to 222) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.99</b> <br/>(1.4 to 2.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1096 children<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Long‐term neurological sequelae other than hearing loss</b> </p> <p><i>defined as sequelae present between 6 weeks after hospital discharge and the last time point reported in the study</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>88 per 1000</b><br/>(51 to 154) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.32</b> <br/>(1.34 to 4.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>901 children<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>dB:</b> decibels; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Limitations in study design: downgraded by one level due to included study at unclear risk of bias in at least one domain.<br/><sup>b</sup>Imprecision: downgraded by one level due to high level of uncertainty in the absolute effects.<br/><sup>c</sup>Imprecision: downgraded by one level due to extremely low sample size and few events.<br/><sup>d</sup>Consistency of effect: downgraded by one level for inconsistency in effect estimates (moderate or high heterogeneity, I² &gt; 50%).<br/><sup>e</sup>Imprecision: downgraded by two levels due to extremely low sample size and no events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Paracetamol for acute bacterial meningitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/full#CD013437-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013437-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Immunoglobulins for acute bacterial meningitis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with acute bacterial meningitis<br/><b>Settings:</b> hospitals, location unclear<br/><b>Intervention:</b> immunoglobulins<br/><b>Comparison:</b> standard treatment plus immunoglobulins versus standard treatment </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Immunoglobulins</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p><i>during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b><br/>(1 to 515) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.19</b> <br/>(0.01 to 3.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 adults<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any hearing loss</b> </p> <p><i>defined as 40 dB or more not detected by the better ear during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any neurological sequelae other than hearing loss</b> </p> <p><i>defined as health consequences of the infection that involve the central nervous system during the follow‐up period. Can include seizure disorder, focal neurological deficit, ataxia, paresis, or psychomotor retardation</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p><i>during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 adults and children<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe hearing loss</b> </p> <p><i>defined as a threshold of 60 dB or more in the better ear or requiring bilateral hearing aid during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term neurological sequelae other than hearing loss</b> </p> <p><i>defined as sequelae present up to 6 weeks after hospital discharge</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Long‐term neurological sequelae other than hearing loss</b> </p> <p><i>defined as sequelae present between 6 weeks after hospital discharge and the last time point reported in the study</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>dB:</b> decibels; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Limitations in study design: downgraded by two levels due to included study at unclear risk of bias in five domains.<br/><sup>b</sup>Imprecision: downgraded by two levels due to extremely low sample size and few events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Immunoglobulins for acute bacterial meningitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/full#CD013437-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013437-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Heparin for acute bacterial meningitis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with acute bacterial meningitis<br/><b>Settings:</b> hospital in Nigeria<br/><b>Intervention:</b> heparin<br/><b>Comparison:</b> standard treatment plus heparin versus standard treatment </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Immunoglobulins</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p><i>during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>572 per 1000</b><br/>(147 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.29</b> <br/>(0.59 to 8.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 adults<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any hearing loss</b> </p> <p><i>defined as 40 dB or more not detected by the better ear during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any neurological sequelae other than hearing loss</b> </p> <p><i>defined as health consequences of the infection that involve the central nervous system during the follow‐up period. Can include seizure disorder, focal neurological deficit, ataxia, paresis, or psychomotor retardation</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p><i>during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe hearing loss</b> </p> <p><i>defined as a threshold of 60 dB or more in the better ear or requiring bilateral hearing aid during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term neurological sequelae other than hearing loss</b> </p> <p><i>defined as sequelae present up to 6 weeks after hospital discharge</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Long‐term neurological sequelae other than hearing loss</b> </p> <p><i>defined as sequelae present between 6 weeks after hospital discharge and the last time point reported in the study</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>dB:</b> decibels; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Limitations in study design: downgraded by two levels due to included study at high or unclear risk of bias in four domains.<br/><sup>b</sup>Imprecision: downgraded by two levels due to extremely low sample size and few events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Heparin for acute bacterial meningitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/full#CD013437-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013437-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Pentoxifylline for acute bacterial meningitis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> children with acute bacterial meningitis<br/><b>Settings:</b> hospital in Paraguay<br/><b>Intervention:</b> pentoxifylline<br/><b>Comparison:</b> standard treatment plus pentoxifylline versus standard treatment </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Immunoglobulins</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p><i>during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>115 per 1000</b><br/>(23 to 573) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> <br/>(0.25 to 6.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 children<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any hearing loss</b> </p> <p><i>defined as 40 dB or more not detected by the better ear during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any neurological sequelae other than hearing loss</b> </p> <p><i>defined as health consequences of the infection that involve the central nervous system during the follow‐up period. Can include seizure disorder, focal neurological deficit, ataxia, paresis, or psychomotor retardation</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p><i>during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe hearing loss</b> </p> <p><i>defined as a threshold of 60 dB or more in the better ear or requiring bilateral hearing aid during the follow‐up period</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Short‐term neurological sequelae other than hearing loss</b> </p> <p><i>defined as sequelae present up to 6 weeks after hospital discharge</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Long‐term neurological sequelae other than hearing loss</b> </p> <p><i>defined as sequelae present between 6 weeks after hospital discharge and the last time point reported in the study</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>dB:</b> decibels; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Limitations in study design: downgraded by two levels due to included study at high or unclear risk of bias in four domains.<br/><sup>b</sup>Imprecision: downgraded by two levels due to extremely low sample size and few events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Pentoxifylline for acute bacterial meningitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/full#CD013437-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013437-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Paracetamol for acute bacterial meningitis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.81, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Any hearing loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.80, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Any neurological sequelae other than hearing loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.98, 2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Severe hearing loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.67, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Short‐term neurologic sequelae <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1096</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [1.40, 2.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Long‐term neurological sequelae <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [1.34, 4.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Paracetamol for acute bacterial meningitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/references#CD013437-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013437-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Immunoglobulins for acute bacterial meningitis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.01, 3.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Immunoglobulins for acute bacterial meningitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/references#CD013437-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013437-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Heparin for acute bacterial meningitis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [0.59, 8.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Heparin for acute bacterial meningitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/references#CD013437-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013437-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Pentoxifylline for acute bacterial meningitis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.25, 6.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Pentoxifylline for acute bacterial meningitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013437.pub2/references#CD013437-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013437.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013437-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013437-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013437-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD013437-note-0010">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013437-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD013437-note-0009">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013437-note-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013437-note-0008">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013437\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013437\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013437\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013437\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013437\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013437\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013437\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013437\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013437\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013437\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013437\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013437\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013437\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013437\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013437\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013437\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013437\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013437\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=zCmos3jT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013437.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013437.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013437.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013437.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013437.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725476436"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013437.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725476440"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013437.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e7c28aefef4b8',t:'MTc0MDcyNTQ3Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 